WO2022068878A1 - 一种抗肿瘤化合物及其制备方法和应用 - Google Patents
一种抗肿瘤化合物及其制备方法和应用 Download PDFInfo
- Publication number
- WO2022068878A1 WO2022068878A1 PCT/CN2021/121721 CN2021121721W WO2022068878A1 WO 2022068878 A1 WO2022068878 A1 WO 2022068878A1 CN 2021121721 W CN2021121721 W CN 2021121721W WO 2022068878 A1 WO2022068878 A1 WO 2022068878A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- independently
- racemate
- meso
- tautomer
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 391
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 4
- 239000000203 mixture Substances 0.000 claims abstract description 281
- 150000003839 salts Chemical class 0.000 claims abstract description 224
- 229910052739 hydrogen Inorganic materials 0.000 claims description 323
- 239000001257 hydrogen Substances 0.000 claims description 269
- 125000001931 aliphatic group Chemical group 0.000 claims description 242
- 229910052736 halogen Inorganic materials 0.000 claims description 218
- 150000002367 halogens Chemical class 0.000 claims description 218
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 189
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 169
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 claims description 169
- 229910052805 deuterium Inorganic materials 0.000 claims description 169
- 229910052722 tritium Inorganic materials 0.000 claims description 169
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims description 168
- 241000720974 Protium Species 0.000 claims description 168
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 145
- 229920006395 saturated elastomer Polymers 0.000 claims description 139
- 150000001413 amino acids Chemical class 0.000 claims description 119
- 125000001424 substituent group Chemical group 0.000 claims description 88
- 238000006467 substitution reaction Methods 0.000 claims description 88
- 239000003446 ligand Substances 0.000 claims description 68
- 125000000623 heterocyclic group Chemical group 0.000 claims description 53
- 125000005549 heteroarylene group Chemical group 0.000 claims description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 33
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 125000000732 arylene group Chemical group 0.000 claims description 29
- 239000003814 drug Substances 0.000 claims description 28
- 235000001014 amino acid Nutrition 0.000 claims description 27
- 229940079593 drug Drugs 0.000 claims description 25
- 229910052799 carbon Inorganic materials 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 125000005842 heteroatom Chemical group 0.000 claims description 17
- 229910052757 nitrogen Inorganic materials 0.000 claims description 17
- 239000000427 antigen Substances 0.000 claims description 15
- 108091007433 antigens Proteins 0.000 claims description 15
- 102000036639 antigens Human genes 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 12
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 12
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 12
- 102100038078 CD276 antigen Human genes 0.000 claims description 11
- 102100025221 CD70 antigen Human genes 0.000 claims description 11
- 101000884279 Homo sapiens CD276 antigen Proteins 0.000 claims description 11
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 11
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 11
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 11
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 claims description 11
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 claims description 11
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 11
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 11
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 11
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 11
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- 101150117918 Tacstd2 gene Proteins 0.000 claims description 9
- 102100027212 Tumor-associated calcium signal transducer 2 Human genes 0.000 claims description 9
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 8
- 102000002029 Claudin Human genes 0.000 claims description 8
- 108050009302 Claudin Proteins 0.000 claims description 8
- 239000011630 iodine Substances 0.000 claims description 8
- 229910052740 iodine Inorganic materials 0.000 claims description 8
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 235000004279 alanine Nutrition 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 6
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 6
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 6
- 239000004472 Lysine Substances 0.000 claims description 6
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims description 6
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 6
- 235000013477 citrulline Nutrition 0.000 claims description 6
- 229960002173 citrulline Drugs 0.000 claims description 6
- 235000018977 lysine Nutrition 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 235000014393 valine Nutrition 0.000 claims description 6
- 239000004474 valine Substances 0.000 claims description 6
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 5
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010046431 Urethral cancer Diseases 0.000 claims description 4
- 206010046458 Urethral neoplasms Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000005017 glioblastoma Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 235000003704 aspartic acid Nutrition 0.000 claims description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 235000013922 glutamic acid Nutrition 0.000 claims description 3
- 239000004220 glutamic acid Substances 0.000 claims description 3
- 235000004400 serine Nutrition 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 63
- 150000002431 hydrogen Chemical class 0.000 claims 62
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 238000003419 tautomerization reaction Methods 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 166
- -1 Sema5b Proteins 0.000 description 87
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 45
- 102000025171 antigen binding proteins Human genes 0.000 description 37
- 108091000831 antigen binding proteins Proteins 0.000 description 37
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 36
- 210000004881 tumor cell Anatomy 0.000 description 36
- 125000004429 atom Chemical group 0.000 description 28
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 27
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 27
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 23
- 239000003795 chemical substances by application Substances 0.000 description 21
- 125000003118 aryl group Chemical group 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 19
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 18
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 18
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 18
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 18
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- 150000007529 inorganic bases Chemical class 0.000 description 18
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 18
- 150000007530 organic bases Chemical class 0.000 description 18
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 13
- 229940127089 cytotoxic agent Drugs 0.000 description 13
- 239000002254 cytotoxic agent Substances 0.000 description 13
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 12
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 12
- 239000012312 sodium hydride Substances 0.000 description 12
- 229910000104 sodium hydride Inorganic materials 0.000 description 12
- 239000012453 solvate Substances 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 11
- 239000000611 antibody drug conjugate Substances 0.000 description 10
- 229940049595 antibody-drug conjugate Drugs 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 125000005647 linker group Chemical group 0.000 description 10
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 9
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 9
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 9
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 9
- NANWDEYOYMUHHG-UHFFFAOYSA-N N1(CCCC1)[P] Chemical compound N1(CCCC1)[P] NANWDEYOYMUHHG-UHFFFAOYSA-N 0.000 description 9
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 102100033579 Trophoblast glycoprotein Human genes 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 9
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 9
- 229910000024 caesium carbonate Inorganic materials 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 235000011181 potassium carbonates Nutrition 0.000 description 9
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000003638 chemical reducing agent Substances 0.000 description 8
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 229910052698 phosphorus Inorganic materials 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000026310 Breast neoplasm Diseases 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 229960002087 pertuzumab Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 7
- 229960000575 trastuzumab Drugs 0.000 description 7
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 6
- 108050007957 Cadherin Proteins 0.000 description 6
- 102000000905 Cadherin Human genes 0.000 description 6
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 6
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 6
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 6
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 6
- 101000798109 Homo sapiens Melanotransferrin Proteins 0.000 description 6
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 description 6
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 description 6
- 102100032818 Integrin alpha-4 Human genes 0.000 description 6
- 239000002841 Lewis acid Substances 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 102100032239 Melanotransferrin Human genes 0.000 description 6
- 241001529936 Murinae Species 0.000 description 6
- 102100035486 Nectin-4 Human genes 0.000 description 6
- 101710043865 Nectin-4 Proteins 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 102100030859 Tissue factor Human genes 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 102100023144 Zinc transporter ZIP6 Human genes 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 102000006495 integrins Human genes 0.000 description 6
- 108010044426 integrins Proteins 0.000 description 6
- 150000007517 lewis acids Chemical class 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 235000011056 potassium acetate Nutrition 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910001868 water Inorganic materials 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- 102100034256 Mucin-1 Human genes 0.000 description 5
- 108010008707 Mucin-1 Proteins 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 150000001721 carbon Chemical group 0.000 description 5
- 239000000562 conjugate Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 229950001460 sacituzumab Drugs 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- 229950007157 zolbetuximab Drugs 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108010063954 Mucins Proteins 0.000 description 4
- 102000015728 Mucins Human genes 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000002947 alkylene group Chemical group 0.000 description 4
- 125000000304 alkynyl group Chemical group 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 235000021443 coca cola Nutrition 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000004530 micro-emulsion Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000003053 toxin Substances 0.000 description 4
- 231100000765 toxin Toxicity 0.000 description 4
- 108700012359 toxins Proteins 0.000 description 4
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 3
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 101150054149 ANGPTL4 gene Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102100036732 Actin, aortic smooth muscle Human genes 0.000 description 3
- 102100026439 Adhesion G protein-coupled receptor E1 Human genes 0.000 description 3
- 102100026402 Adhesion G protein-coupled receptor E2 Human genes 0.000 description 3
- 108010003133 Aldo-Keto Reductase Family 1 Member C2 Proteins 0.000 description 3
- 102100026446 Aldo-keto reductase family 1 member C1 Human genes 0.000 description 3
- 102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 description 3
- 102100040121 Allograft inflammatory factor 1 Human genes 0.000 description 3
- 102000045205 Angiopoietin-Like Protein 4 Human genes 0.000 description 3
- 108700042530 Angiopoietin-Like Protein 4 Proteins 0.000 description 3
- 102000013918 Apolipoproteins E Human genes 0.000 description 3
- 108010025628 Apolipoproteins E Proteins 0.000 description 3
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 description 3
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 3
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 3
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 3
- 108010074708 B7-H1 Antigen Proteins 0.000 description 3
- 102100035656 BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Human genes 0.000 description 3
- 229910015900 BF3 Inorganic materials 0.000 description 3
- 102100032412 Basigin Human genes 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 102100027052 Bone morphogenetic protein receptor type-1B Human genes 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 3
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 3
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 3
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 3
- 102100031658 C-X-C chemokine receptor type 5 Human genes 0.000 description 3
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 3
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 description 3
- 108010008629 CA-125 Antigen Proteins 0.000 description 3
- 102100031168 CCN family member 2 Human genes 0.000 description 3
- 102100024210 CD166 antigen Human genes 0.000 description 3
- 102100024220 CD180 antigen Human genes 0.000 description 3
- 101150013553 CD40 gene Proteins 0.000 description 3
- 102100035350 CUB domain-containing protein 1 Human genes 0.000 description 3
- 102100024155 Cadherin-11 Human genes 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102100036369 Carbonic anhydrase 6 Human genes 0.000 description 3
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 description 3
- 102100032219 Cathepsin D Human genes 0.000 description 3
- 102100035654 Cathepsin S Human genes 0.000 description 3
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- 102100024335 Collagen alpha-1(VII) chain Human genes 0.000 description 3
- 102100024338 Collagen alpha-3(VI) chain Human genes 0.000 description 3
- 102100037077 Complement C1q subcomponent subunit A Human genes 0.000 description 3
- 102100037085 Complement C1q subcomponent subunit B Human genes 0.000 description 3
- 102100032768 Complement receptor type 2 Human genes 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 102100026139 DNA damage-inducible transcript 4 protein Human genes 0.000 description 3
- 102100036466 Delta-like protein 3 Human genes 0.000 description 3
- 102100033553 Delta-like protein 4 Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 3
- 102100020743 Dipeptidase 1 Human genes 0.000 description 3
- 102100026245 E3 ubiquitin-protein ligase RNF43 Human genes 0.000 description 3
- 102000010180 Endothelin receptor Human genes 0.000 description 3
- 108050001739 Endothelin receptor Proteins 0.000 description 3
- 108010055196 EphA2 Receptor Proteins 0.000 description 3
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 3
- 102100033942 Ephrin-A4 Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102100031517 Fc receptor-like protein 1 Human genes 0.000 description 3
- 101710120224 Fc receptor-like protein 1 Proteins 0.000 description 3
- 102100031511 Fc receptor-like protein 2 Human genes 0.000 description 3
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 3
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 3
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 3
- 102100022629 Fructose-2,6-bisphosphatase Human genes 0.000 description 3
- 102100036939 G-protein coupled receptor 20 Human genes 0.000 description 3
- 101150030514 GPC1 gene Proteins 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100030385 Granzyme B Human genes 0.000 description 3
- 102100030595 HLA class II histocompatibility antigen gamma chain Human genes 0.000 description 3
- 102100031546 HLA class II histocompatibility antigen, DO beta chain Human genes 0.000 description 3
- 102100028006 Heme oxygenase 1 Human genes 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 101000929319 Homo sapiens Actin, aortic smooth muscle Proteins 0.000 description 3
- 101000718225 Homo sapiens Adhesion G protein-coupled receptor E1 Proteins 0.000 description 3
- 101000718211 Homo sapiens Adhesion G protein-coupled receptor E2 Proteins 0.000 description 3
- 101000718028 Homo sapiens Aldo-keto reductase family 1 member C1 Proteins 0.000 description 3
- 101000890626 Homo sapiens Allograft inflammatory factor 1 Proteins 0.000 description 3
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 description 3
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 3
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 3
- 101000803294 Homo sapiens BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 Proteins 0.000 description 3
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 3
- 101000984546 Homo sapiens Bone morphogenetic protein receptor type-1B Proteins 0.000 description 3
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 3
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 description 3
- 101000922405 Homo sapiens C-X-C chemokine receptor type 5 Proteins 0.000 description 3
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 3
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 description 3
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 description 3
- 101000980840 Homo sapiens CD166 antigen Proteins 0.000 description 3
- 101000980829 Homo sapiens CD180 antigen Proteins 0.000 description 3
- 101000737742 Homo sapiens CUB domain-containing protein 1 Proteins 0.000 description 3
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 description 3
- 101000714525 Homo sapiens Carbonic anhydrase 6 Proteins 0.000 description 3
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 description 3
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 3
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 3
- 101000947086 Homo sapiens Cathepsin S Proteins 0.000 description 3
- 101000909498 Homo sapiens Collagen alpha-1(VII) chain Proteins 0.000 description 3
- 101000909506 Homo sapiens Collagen alpha-3(VI) chain Proteins 0.000 description 3
- 101000740726 Homo sapiens Complement C1q subcomponent subunit A Proteins 0.000 description 3
- 101000740680 Homo sapiens Complement C1q subcomponent subunit B Proteins 0.000 description 3
- 101000941929 Homo sapiens Complement receptor type 2 Proteins 0.000 description 3
- 101000912753 Homo sapiens DNA damage-inducible transcript 4 protein Proteins 0.000 description 3
- 101100499854 Homo sapiens DPEP1 gene Proteins 0.000 description 3
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 description 3
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 description 3
- 101000692702 Homo sapiens E3 ubiquitin-protein ligase RNF43 Proteins 0.000 description 3
- 101000925259 Homo sapiens Ephrin-A4 Proteins 0.000 description 3
- 101000846911 Homo sapiens Fc receptor-like protein 2 Proteins 0.000 description 3
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 description 3
- 101000823463 Homo sapiens Fructose-2,6-bisphosphatase Proteins 0.000 description 3
- 101001071355 Homo sapiens G-protein coupled receptor 20 Proteins 0.000 description 3
- 101001009603 Homo sapiens Granzyme B Proteins 0.000 description 3
- 101001082627 Homo sapiens HLA class II histocompatibility antigen gamma chain Proteins 0.000 description 3
- 101000866281 Homo sapiens HLA class II histocompatibility antigen, DO beta chain Proteins 0.000 description 3
- 101001079623 Homo sapiens Heme oxygenase 1 Proteins 0.000 description 3
- 101000606465 Homo sapiens Inactive tyrosine-protein kinase 7 Proteins 0.000 description 3
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 description 3
- 101001044927 Homo sapiens Insulin-like growth factor-binding protein 3 Proteins 0.000 description 3
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 3
- 101001082070 Homo sapiens Interferon alpha-inducible protein 6 Proteins 0.000 description 3
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 description 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 3
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 3
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 description 3
- 101000604590 Homo sapiens Keratin, type I cuticular Ha3-I Proteins 0.000 description 3
- 101001039113 Homo sapiens Leucine-rich repeat-containing protein 15 Proteins 0.000 description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 3
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 3
- 101001065609 Homo sapiens Lumican Proteins 0.000 description 3
- 101001038507 Homo sapiens Ly6/PLAUR domain-containing protein 3 Proteins 0.000 description 3
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 description 3
- 101001065568 Homo sapiens Lymphocyte antigen 6E Proteins 0.000 description 3
- 101001018034 Homo sapiens Lymphocyte antigen 75 Proteins 0.000 description 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 3
- 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 description 3
- 101001011886 Homo sapiens Matrix metalloproteinase-16 Proteins 0.000 description 3
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 3
- 101000956317 Homo sapiens Membrane-spanning 4-domains subfamily A member 4A Proteins 0.000 description 3
- 101001014567 Homo sapiens Membrane-spanning 4-domains subfamily A member 7 Proteins 0.000 description 3
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 description 3
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 description 3
- 101000628535 Homo sapiens Metalloreductase STEAP2 Proteins 0.000 description 3
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 3
- 101000604123 Homo sapiens Noggin Proteins 0.000 description 3
- 101000897042 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 description 3
- 101000595746 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Proteins 0.000 description 3
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 3
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 3
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 description 3
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 3
- 101000881678 Homo sapiens Prolyl hydroxylase EGLN3 Proteins 0.000 description 3
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 3
- 101000804792 Homo sapiens Protein Wnt-5a Proteins 0.000 description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 3
- 101000835984 Homo sapiens SLIT and NTRK-like protein 6 Proteins 0.000 description 3
- 101000701446 Homo sapiens Stanniocalcin-2 Proteins 0.000 description 3
- 101000577874 Homo sapiens Stromelysin-2 Proteins 0.000 description 3
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 description 3
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 3
- 101000835745 Homo sapiens Teratocarcinoma-derived growth factor 1 Proteins 0.000 description 3
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 description 3
- 101000834948 Homo sapiens Tomoregulin-2 Proteins 0.000 description 3
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 3
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 3
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 3
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 3
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 3
- 101000904724 Homo sapiens Transmembrane glycoprotein NMB Proteins 0.000 description 3
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 description 3
- 101000610604 Homo sapiens Tumor necrosis factor receptor superfamily member 10B Proteins 0.000 description 3
- 101000679921 Homo sapiens Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 description 3
- 101000807561 Homo sapiens Tyrosine-protein kinase receptor UFO Proteins 0.000 description 3
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 description 3
- 101000808114 Homo sapiens Uroplakin-1b Proteins 0.000 description 3
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 3
- 101000685848 Homo sapiens Zinc transporter ZIP6 Proteins 0.000 description 3
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 3
- 102100039813 Inactive tyrosine-protein kinase 7 Human genes 0.000 description 3
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 description 3
- 102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 3
- 102100022338 Integrin alpha-M Human genes 0.000 description 3
- 102100027354 Interferon alpha-inducible protein 6 Human genes 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 102000004889 Interleukin-6 Human genes 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- 102100038185 Keratin, type I cuticular Ha3-I Human genes 0.000 description 3
- 102100034845 KiSS-1 receptor Human genes 0.000 description 3
- 108010076800 Kisspeptin-1 Receptors Proteins 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- 101710159002 L-lactate oxidase Proteins 0.000 description 3
- 102000017578 LAG3 Human genes 0.000 description 3
- 102100040645 Leucine-rich repeat-containing protein 15 Human genes 0.000 description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 239000012448 Lithium borohydride Substances 0.000 description 3
- 102100032114 Lumican Human genes 0.000 description 3
- 102100040281 Ly6/PLAUR domain-containing protein 3 Human genes 0.000 description 3
- 102100032131 Lymphocyte antigen 6E Human genes 0.000 description 3
- 102100033486 Lymphocyte antigen 75 Human genes 0.000 description 3
- 102100025069 MARVEL domain-containing protein 1 Human genes 0.000 description 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 3
- 102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 3
- 101150031009 Mcpt8 gene Proteins 0.000 description 3
- 102100039373 Membrane cofactor protein Human genes 0.000 description 3
- 102100032512 Membrane-spanning 4-domains subfamily A member 7 Human genes 0.000 description 3
- 108090000015 Mesothelin Proteins 0.000 description 3
- 102000003735 Mesothelin Human genes 0.000 description 3
- 102100025096 Mesothelin Human genes 0.000 description 3
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 description 3
- 102100026711 Metalloreductase STEAP2 Human genes 0.000 description 3
- 102100023123 Mucin-16 Human genes 0.000 description 3
- 101100262697 Mus musculus Axl gene Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 description 3
- 102100038454 Noggin Human genes 0.000 description 3
- 102100021969 Nucleotide pyrophosphatase Human genes 0.000 description 3
- 108090000304 Occludin Proteins 0.000 description 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102100037603 P2X purinoceptor 5 Human genes 0.000 description 3
- 101710189969 P2X purinoceptor 5 Proteins 0.000 description 3
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 102100036056 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform Human genes 0.000 description 3
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 3
- 102100035194 Placenta growth factor Human genes 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 3
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 3
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 3
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 3
- 101710202113 Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 description 3
- 102100037247 Prolyl hydroxylase EGLN3 Human genes 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 3
- 102100026858 Protein-lysine 6-oxidase Human genes 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 3
- 108091006938 SLC39A6 Proteins 0.000 description 3
- 102100025504 SLIT and NTRK-like protein 6 Human genes 0.000 description 3
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 3
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 3
- 102000046202 Sodium-Phosphate Cotransporter Proteins Human genes 0.000 description 3
- 102100030510 Stanniocalcin-2 Human genes 0.000 description 3
- 102100028848 Stromelysin-2 Human genes 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 3
- 102100035721 Syndecan-1 Human genes 0.000 description 3
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 3
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 3
- 102100033456 TGF-beta receptor type-1 Human genes 0.000 description 3
- 102100026404 Teratocarcinoma-derived growth factor 1 Human genes 0.000 description 3
- 108010000499 Thromboplastin Proteins 0.000 description 3
- 102100026160 Tomoregulin-2 Human genes 0.000 description 3
- 102100023489 Transcription factor 4 Human genes 0.000 description 3
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 3
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 description 3
- 102000009618 Transforming Growth Factors Human genes 0.000 description 3
- 108010009583 Transforming Growth Factors Proteins 0.000 description 3
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 3
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 3
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 3
- 101710190034 Trophoblast glycoprotein Proteins 0.000 description 3
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 3
- 102100040112 Tumor necrosis factor receptor superfamily member 10B Human genes 0.000 description 3
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 description 3
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 description 3
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 description 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 3
- 102100037236 Tyrosine-protein kinase receptor UFO Human genes 0.000 description 3
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 description 3
- 102100038853 Uroplakin-1b Human genes 0.000 description 3
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 3
- 102000043366 Wnt-5a Human genes 0.000 description 3
- ILXDAXZQNSOSAE-UHFFFAOYSA-N [AlH3].[Cl] Chemical compound [AlH3].[Cl] ILXDAXZQNSOSAE-UHFFFAOYSA-N 0.000 description 3
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000000000 cycloalkoxy group Chemical group 0.000 description 3
- 125000005366 cycloalkylthio group Chemical group 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229940127276 delta-like ligand 3 Drugs 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002270 dispersing agent Substances 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 3
- 201000004101 esophageal cancer Diseases 0.000 description 3
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 229910000103 lithium hydride Inorganic materials 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229910017604 nitric acid Inorganic materials 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 239000000346 nonvolatile oil Substances 0.000 description 3
- 201000002528 pancreatic cancer Diseases 0.000 description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 108091006284 sodium-phosphate co-transporters Proteins 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 3
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 101000935642 Homo sapiens Phosphoinositide 3-kinase adapter protein 1 Proteins 0.000 description 2
- 101000595907 Homo sapiens Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Proteins 0.000 description 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102100028238 Phosphoinositide 3-kinase adapter protein 1 Human genes 0.000 description 2
- 102100035198 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 Human genes 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 229940102213 injectable suspension Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 108040003607 interleukin-13 receptor activity proteins Proteins 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-L 2-(carboxymethyl)-2-hydroxysuccinate Chemical compound [O-]C(=O)CC(O)(C(=O)O)CC([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-L 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 101100520033 Dictyostelium discoideum pikC gene Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100035139 Folate receptor alpha Human genes 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 description 1
- 101000595904 Homo sapiens Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102100035202 Procollagen-lysine,2-oxoglutarate 5-dioxygenase 1 Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- WJTCGQSWYFHTAC-UHFFFAOYSA-N cyclooctane Chemical compound C1CCCCCCC1 WJTCGQSWYFHTAC-UHFFFAOYSA-N 0.000 description 1
- 239000004914 cyclooctane Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000001620 monocyclic carbocycle group Chemical group 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 150000003873 salicylate salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 125000003003 spiro group Chemical group 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000002100 tumorsuppressive effect Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present application relates to the field of biomedicine, in particular to an anti-tumor compound and its preparation method and application.
- camptothecin derivatives small cytotoxic molecules for antibody drug conjugates can be camptothecin derivatives, which have antitumor effects by inhibiting topoisomerase I. Camptothecin derivatives can be used in antibody drug conjugates (ADC). However, there is still a need for further development of camptothecin derivatives and ADC drugs with better efficacy and/or safety.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof , which may have one or more effects selected from the group consisting of: (1) having inhibitory activity against tumor cell proliferation in vitro; (2) having targeted inhibitory properties; (3) having plasma stability; (4) (5) Bystander Effect; (6) Anti-transporter transport ability; (7) In vivo tumor targeting ability; and (8) Good in vivo safety.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof A salt for use, wherein the compound comprises the structure of formula (II-A):
- Ring A is selected from the group consisting of 3- to 10-membered saturated or partially unsaturated heterocyclyl, and 3- to 10-membered saturated or partially unsaturated carbocyclyl, wherein said Ring A is surrounded by 0 or at least 1 Substituent R 1a is substituted;
- Ring A is a 3- to 10-membered saturated or partially unsaturated carbocyclyl, said Ring A is substituted with p L 2 that are not R n ;
- Ring A is a 3- to 10-membered saturated or partially unsaturated heterocyclyl group, said Ring A is substituted with p L 2 ;
- L 2 is -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect a ligand
- each R 1a , R 2a , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R n is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, - OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O) R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O) R, -N(R)SO 2 R, or a C 1-6 aliphatic group optionally substituted by R;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO2 , -CN, -OH, -SH, -NH2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- n are each independently selected from an integer of at least 0, and p is an integer of at least 1.
- the present application provides a compound represented by general formula (II-Ex) or its tautomer, meso, racemate, enantiomer, diastereomer body, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
- Ring A is selected from the group consisting of 3- to 10-membered saturated or partially unsaturated heterocyclyl, and 3- to 10-membered saturated or partially unsaturated carbocyclyl, wherein said Ring A is surrounded by 0 or at least 1 Substituent R 1a is substituted;
- Ring A is a 3- to 10-membered saturated or partially unsaturated carbocyclyl, said Ring A is substituted with p L 2 that are not R n ;
- Ring A is a 3- to 10-membered saturated or partially unsaturated heterocyclyl group, said Ring A is substituted with p L 2 ;
- L 2 is -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect a ligand
- each R 1a , R 2a , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R n is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, - OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O) R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O) R, -N(R)SO 2 R, or a C 1-6 aliphatic group optionally substituted by R;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO2 , -CN, -OH, -SH, -NH2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- n are each independently selected from an integer of at least 0, and p is an integer of at least 1.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof
- the salt used contains the structure of formula (II-C x ):
- L is -L a -L b -L c -;
- the -L a - is selected from the following group:
- W is -(C(R wa )(R wb )) wn -
- Y is -(OCH 2 CH 2 ) yn -O yp -
- Z is -(C(R za )(R zb )) zn ;
- wn is selected from an integer of at least 0,
- yn is selected from an integer of at least 0 and yp is 0 or 1;
- zn is selected from an integer of at least 0,
- -Cyr- is selected from the group consisting of 6 to 10 membered arylene, 5 to 8 membered heteroarylene, 3 to 10 membered heterocyclylene, and 3 to 10 membered saturated or partially unsaturated carbocyclylene , wherein the -Cyr- is unsubstituted or independently substituted with at least 1 substituent R cx ;
- each Rwa , Rwb , Rza , Rzb, Rwx , Rzx , Rcx is independently hydrogen, protium , deuterium, tritium, halogen, -NO2 , -CN, -ORr , -SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O) R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), -OC (O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic group optionally substituted by R r ;
- each R r , R ra , R rb is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the -L c - is selected from the following group:
- R L1 and R L2 are each independently selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, and C 1-6 aliphatic groups;
- Ring A is selected from the group consisting of 3- to 10-membered saturated or partially unsaturated heterocyclyl, and 3- to 10-membered saturated or partially unsaturated carbocyclyl, wherein said Ring A is surrounded by 0 or at least 1 Substituent R 1a is substituted;
- Ring A is a 3- to 10-membered saturated or partially unsaturated carbocyclyl, said Ring A is substituted with p L 2 that are not R n ;
- Ring A is a 3- to 10-membered saturated or partially unsaturated heterocyclyl group, said Ring A is substituted with p L 2 ;
- L 2 is -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect a ligand
- each R 1a , R 2a , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R n is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, - OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O) R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O) R, -N(R)SO 2 R, or a C 1-6 aliphatic group optionally substituted by R;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO2 , -CN, -OH, -SH, -NH2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- n are each independently selected from an integer of at least 0, and p is an integer of at least 1.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof
- the salt used contains the structure of formula (II-Dx):
- Ab is a ligand, and the average number of connections Na is an integer or decimal from 1 to 10;
- L is -L a -L b -L c -;
- the -L a - is selected from the following group:
- W is -(C(R wa )(R wb )) wn -
- Y is -(OCH 2 CH 2 ) yn -O yp -
- Z is -(C(R za )(R zb )) zn ;
- wn is selected from an integer of at least 0,
- yn is selected from an integer of at least 0 and yp is 0 or 1;
- zn is selected from an integer of at least 0,
- -Cyr- is selected from the group consisting of 6 to 10 membered arylene, 5 to 8 membered heteroarylene, 3 to 10 membered heterocyclylene, and 3 to 10 membered saturated or partially unsaturated carbocyclylene , wherein the -Cyr- is unsubstituted or independently substituted with at least 1 substituent R cx ;
- each Rwa , Rwb , Rza , Rzb, Rwx , Rzx , Rcx is independently hydrogen, protium , deuterium, tritium, halogen, -NO2 , -CN, -ORr , -SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O) R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), -OC (O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic group optionally substituted by R r ;
- each R r , R ra , R rb is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the -L c - is selected from the following group:
- R L1 and R L2 are each independently selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, and C 1-6 aliphatic groups;
- Ring A is selected from the group consisting of 3- to 10-membered saturated or partially unsaturated heterocyclyl, and 3- to 10-membered saturated or partially unsaturated carbocyclyl, wherein said Ring A is surrounded by 0 or at least 1 Substituent R 1a is substituted;
- Ring A is a 3- to 10-membered saturated or partially unsaturated carbocyclyl, said Ring A is substituted with p L 2 that are not R n ;
- Ring A is a 3- to 10-membered saturated or partially unsaturated heterocyclyl group, said Ring A is substituted with p L 2 ;
- L 2 is -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect a ligand
- each R 1a , R 2a , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R n is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, - OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O) R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O) R, -N(R)SO 2 R, or a C 1-6 aliphatic group optionally substituted by R;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO2 , -CN, -OH, -SH, -NH2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- n are each independently selected from an integer of at least 0, and p is an integer of at least 1.
- the present application provides a compound represented by the general formula (II-F x ) or its tautomer, meso, racemate, enantiomer, and diastereomer body, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
- the L x is L ax -L b -L c -;
- the Lax - is selected from the following group:
- R hal is iodine or bromine
- W is -(C(R wa )(R wb )) wn -
- Y is -(OCH 2 CH 2 ) yn -O yp -
- Z is -(C(R za )(R zb )) zn ;
- wn is selected from an integer of at least 0,
- yn is selected from an integer of at least 0 and yp is 0 or 1;
- zn is selected from an integer of at least 0,
- -Cyr- is selected from the group consisting of 6 to 10 membered arylene, 5 to 8 membered heteroarylene, 3 to 10 membered heterocyclylene, and 3 to 10 membered saturated or partially unsaturated carbocyclylene , wherein the -Cyr- is unsubstituted or independently substituted with at least 1 substituent R cx ;
- each Rwa , Rwb , Rza , Rzb, Rwx , Rzx , Rcx is independently hydrogen, protium , deuterium, tritium, halogen, -NO2 , -CN, -ORr , -SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O) R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), -OC (O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic group optionally substituted by R r ;
- each R r , R ra , R rb is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the -L c - is selected from the following group:
- R L1 and R L2 are each independently selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, and C 1-6 aliphatic groups;
- Ring A is selected from the group consisting of 3- to 10-membered saturated or partially unsaturated heterocyclyl, and 3- to 10-membered saturated or partially unsaturated carbocyclyl, wherein said Ring A is surrounded by 0 or at least 1 Substituent R 1a is substituted;
- Ring A is a 3- to 10-membered saturated or partially unsaturated carbocyclyl, said Ring A is substituted with p L 2 that are not R n ;
- Ring A is a 3- to 10-membered saturated or partially unsaturated heterocyclyl group, said Ring A is substituted with p L 2 ;
- L 2 is -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect a ligand
- each R 1a , R 2a , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R n is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, - OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O) R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O) R, -N(R)SO 2 R, or a C 1-6 aliphatic group optionally substituted by R;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO2 , -CN, -OH, -SH, -NH2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- n are each independently selected from an integer of at least 0, and p is an integer of at least 1.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof
- Use salts that contain the structure of the following groups:
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof A useful salt, wherein the compound comprises the structure of formula (III-A):
- X is -L 1 -CH 2 -C(O)-;
- each of R 2 , R 3a , R 3b , R 4b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ) , -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or any of R optionally substituted C 1-6 aliphatic groups;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , - SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group;
- n is selected from an integer of at least 1;
- R 1 is -O- or -HN-
- the present application provides a compound represented by general formula (III-E) or its tautomer, meso, racemate, enantiomer and diastereomer , or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
- X is -L 1 -CH 2 -C(O)-;
- each of R 2 , R 3a , R 3b , R 4b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ) , -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or any of R optionally substituted C 1-6 aliphatic groups;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , - SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group;
- n is selected from an integer of at least 1;
- R 1 is -O- or -HN-
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof
- the salt used contains the structure shown in formula (III-C):
- L is -L a -L b -L c -;
- the -L a - is selected from the following group:
- W is -(C(R wa )(R wb )) wn -
- Y is -(OCH 2 CH 2 ) yn -O yp
- Z is -(C(R za )(R zb )) zn ,
- wn is selected from an integer of at least 0,
- yn is selected from an integer of at least 0 and yp is 0 or 1;
- zn is selected from an integer of at least 0,
- -Cyr- is selected from the group consisting of 6 to 10 membered arylene, 5 to 8 membered heteroarylene, 3 to 10 membered heterocyclylene, and 3 to 10 membered saturated or partially unsaturated carbocyclylene , wherein the -Cyr- is unsubstituted or independently substituted with at least 1 substituent R cx ;
- each Rwa , Rwb , Rza , Rzb, Rwx , Rzx , Rcx is independently hydrogen, protium , deuterium, tritium, halogen, -NO2 , -CN, -ORr , -SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O) R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), -OC (O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic group optionally substituted by R r ;
- each R r , R ra , R rb is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the -L c - is selected from the following group:
- R L1 and R L2 are each independently selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, and C 1-6 aliphatic groups;
- X is -L 1 -CH 2 -C(O)-;
- each of R 2 , R 3a , R 3b , R 4b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ) , -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or any of R optionally substituted C 1-6 aliphatic groups;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , - SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group;
- n is selected from an integer of at least 1;
- R 1 is -O- or -HN-
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof
- the salt used which comprises the structure shown in formula (III-D):
- Ab is a ligand, and the average number of connections Na is an integer or decimal from 1 to 10;
- L is -L a -L b -L c -;
- the -L a - is selected from the following group:
- W is -(C(R wa )(R wb )) wn -
- Y is -(OCH 2 CH 2 ) yn -O yp
- Z is -(C(R za )(R zb )) zn ,
- wn is selected from an integer of at least 0,
- yn is selected from an integer of at least 0 and yp is 0 or 1;
- zn is selected from an integer of at least 0,
- -Cyr- is selected from the group consisting of 6 to 10 membered arylene, 5 to 8 membered heteroarylene, 3 to 10 membered heterocyclylene, and 3 to 10 membered saturated or partially unsaturated carbocyclylene , wherein the -Cyr- is unsubstituted or independently substituted with at least 1 substituent R cx ;
- each Rwa , Rwb , Rza , Rzb, Rwx , Rzx , Rcx is independently hydrogen, protium , deuterium, tritium, halogen, -NO2 , -CN, -ORr , -SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O) R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), -OC (O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic group optionally substituted by R r ;
- each R r , R ra , R rb is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the -L c - is selected from the following group:
- R L1 and R L2 are each independently selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, and C 1-6 aliphatic groups;
- X is -L 1 -CH 2 -C(O)-;
- each of R 2 , R 3a , R 3b , R 4b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ) , -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or any of R optionally substituted C 1-6 aliphatic groups;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , - SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group;
- n is selected from an integer of at least 1;
- R 1 is -O- or -HN-
- the present application provides a compound represented by general formula (III-F) or its tautomer, meso, racemate, enantiomer, and diastereomer , or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
- the L x is L ax -L b -L c -;
- the Lax - is selected from the following group:
- R hal is iodine or bromine
- W is -(C(R wa )(R wb )) wn -
- Y is -(OCH 2 CH 2 ) yn -O yp
- Z is -(C(R za )(R zb )) zn ,
- wn is selected from an integer of at least 0,
- yn is selected from an integer of at least 0 and yp is 0 or 1;
- zn is selected from an integer of at least 0,
- -Cyr- is selected from the group consisting of 6 to 10 membered arylene, 5 to 8 membered heteroarylene, 3 to 10 membered heterocyclylene, and 3 to 10 membered saturated or partially unsaturated carbocyclylene , wherein the -Cyr- is unsubstituted or independently substituted with at least 1 substituent R cx ;
- each Rwa , Rwb , Rza , Rzb, Rwx , Rzx , Rcx is independently hydrogen, protium , deuterium, tritium, halogen, -NO2 , -CN, -ORr , -SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O) R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), -OC (O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic group optionally substituted by R r ;
- each R r , R ra , R rb is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the -L c - is selected from the following group:
- R L1 and R L2 are each independently selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, and C 1-6 aliphatic groups;
- X is -L 1 -CH 2 -C(O)-;
- each of R 2 , R 3a , R 3b , R 4b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ) , -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or any of R optionally substituted C 1-6 aliphatic groups;
- each R, R a , R b is independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , - SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group;
- n is selected from an integer of at least 1;
- R 1 is -O- or -HN-
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable form thereof Useful salts, wherein the Ligand Drug Conjugate comprises the structure of the following group:
- the application provides the preparation of a compound of the application or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof
- a method of a pharmaceutically acceptable salt comprising contacting a ligand Ab with a structure represented by formula (II-F x ) of the present application.
- the application provides the preparation of a compound of the application or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof
- a method of a pharmaceutically acceptable salt comprising contacting a ligand Ab with a structure represented by formula (III-F) of the present application.
- the application provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound of the application or its tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
- the present application provides a compound containing the present application or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof.
- a pharmaceutically acceptable salt and/or the pharmaceutical composition of the present application in the preparation of a medicament for treating and/or preventing tumors.
- Figures 1 to 16 respectively show the results of in vivo tumor inhibition by the compounds of the present application.
- the term "ligand” generally refers to a macromolecular compound capable of recognizing and binding to an antigen or receptor associated with a target cell.
- the role of the ligand can be to present the drug to the target cell population that binds to the ligand, including but not limited to protein hormones, lectins, growth factors, antibodies, or others that can bind to cells, receptors and/or antigens molecule.
- the ligand can be represented as Ab, and the ligand antigen forms a bond with the connecting unit through the heteroatom on the ligand, which can be an antibody or an antigen-binding fragment thereof, and the antibody can be selected from chimeric antibodies, human-derived antibody, fully human, or murine; the antibody may be a monoclonal antibody.
- the antibody may be an antibody targeting the following targets: HER2, HER3, B7H3, TROP2, Claudin 18.2, CD30, CD33, CD70 or EGFR.
- the antibody may be an antibody targeting the following targets: 5T4, AGS-16, ANGPTL4, ApoE, CD19, CTGF, CXCR5, FGF2, MCPT8, MFI2, MS4A7, NCA, Sema5b, SLITRK6, STC2, TGF, 0772P, 5T4, ACTA2, ADGRE1, AG-7, AIF1, AKR1C1, AKR1C2, ASLG659, Axl, B7H3, BAFF-R, BCMA, BMPR1B, BNIP3, C1QA, C1QB, CA6, CADM1, CCD79b, CCL5, CCR5, CCR7, CD1lc, CD123, CD138, CD142, CD147, CD166, CD19, CD19, CD22, CD21, CD20, CD205, CD22, CD223, CD228, CD25, CD30, CD33, CD37, CD38, CD40, CD45, CD45 (PTPRC), CD46, CD47 , CD49D (IT), I
- cytotoxic drug generally refers to a toxic drug, which may have strong chemical molecules within tumor cells that disrupt their normal growth. Cytotoxic drugs can kill tumor cells at high enough concentrations.
- the "cytotoxic drug” may include toxins, such as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, radioisotopes (eg At 211 , I 131 , I 125 , Y 90 , Re 186 , Re 188 ) , Sm 153 , Bi 212 , P 32 or radioisotopes of Lu), toxic drugs, chemotherapeutic drugs, antibiotics and nucleolysins, for example, can be toxic drugs, including but not limited to camptothecin derivatives, for example, can be The tree alkaloid derivative ixatecan (chemical name: (1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H
- linker structure generally refers to a chemical structural fragment or bond with one end connected to a ligand and the other end to a cytotoxic drug. Other linkers can also be connected to the cytotoxic drug.
- the direct or indirect linking of the ligands may refer to that the group is directly linked to the ligands through covalent bonds, or may be linked to the ligands through a linker structure.
- the linker structure may be the structures shown in -L ax -L b -L c - and or -L a -L b -L c - described herein.
- chemical fragments comprising acid-labile linker structures (eg, hydrazones), protease-sensitive (eg, peptidase-sensitive) linker structures, photolabile linker structures, dimethyl linker structures, or disulfide-containing linker structures may be used or bond as a linker structure.
- acid-labile linker structures eg, hydrazones
- protease-sensitive linker structures eg, peptidase-sensitive linker structures
- photolabile linker structures eg, dimethyl linker structures
- disulfide-containing linker structures may be used or bond as a linker structure.
- the term "optionally linked to other molecular moieties" of a structure generally means that the structure is not linked to any other chemical structure, or that the structure is linked to one or more other chemical structures different from the structure (eg, the ligands described herein) are linked (eg, by chemical bonds, or by linker structures).
- ligand-drug conjugate generally refers to a ligand linked to a biologically active cytotoxic drug through a stable linking unit.
- ligand-drug conjugate may be an antibody-drug conjugate (antibody drug conjugate, ADC), and the ADC may refer to the combination of monoclonal antibodies or antibody fragments with biological Active cytotoxic drugs are linked.
- antibody or antigen-binding fragment thereof generally refers to immunological binding reagents extending to all antibodies from all species, including dimeric, trimeric and multimeric antibodies; bispecific antibodies ; chimeric antibodies; fully human antibodies; humanized antibodies; recombinant and engineered antibodies and fragments thereof.
- the term “antibody or fragment thereof” may refer to any antibody-like molecule having an antigen binding region, and the term includes fragments of small molecules such as Fab', Fab, F(ab') 2 , single domain antibodies (DABs), Fv, scFv (single chain Fv), linear antibodies, diabodies, etc.
- antigen-binding fragment can refer to one or more fragments of an antibody that retain the ability to specifically bind an antigen.
- fragments of full-length antibodies can be used for the antigen-binding function of antibodies. Techniques for making and using various antibody-based constructs and fragments are well known in the art.
- the antibody may include: anti-HER2 (ErbB2) antibody, anti-EGFR antibody, anti-B7-H3 antibody, anti-c-Met antibody, anti-HER3 (ErbB3) antibody, anti-HER4 (ErbB4) antibody, anti-CD20 antibody, anti-CD22 antibody , Anti-CD30 Antibody, Anti-CD33 Antibody, Anti-CD44 Antibody, Anti-CD56 Antibody, Anti-CD70 Antibody, Anti-CD73 Antibody, Anti-CD105 Antibody, Anti-CEA Antibody, Anti-A33 Antibody, Anti-Cripto Antibody, Anti-EphA2 Antibody, Anti-G250 Antibody, Anti- One or more of MUCl antibody, anti-Lewis Y antibody, anti-TROP2 antibody, anti-Claudin 18.2 antibody, anti-VEGFR antibody, anti-GPNMB antibody, anti-Integrin antibody, anti-PSMA antibody, anti-Tenascin-C antibody, anti-SLC44A4 antibody or anti-Mesothel
- chimeric antibody generally refers to an antibody in which the variable region of a murine antibody is fused with the constant region of a human antibody, which can alleviate the immune response induced by the murine antibody.
- a hybridoma that secretes a mouse-specific monoclonal antibody can be established, and then the variable region gene can be cloned from the mouse hybridoma cell, and the constant region gene of the human antibody can be cloned according to the needs.
- the human constant region gene is connected into a chimeric gene and inserted into an expression vector, and the chimeric antibody molecule can be expressed in a eukaryotic system or a prokaryotic system.
- humanized antibody also known as CDR-grafted antibody
- CDR-grafted antibody generally refers to the grafting of murine CDR sequences into the framework of human antibody variable regions, i.e. different Types of human germline antibody framework sequences produced in antibodies.
- the heterologous reaction induced by chimeric antibodies can be overcome because they carry a large amount of murine protein components.
- framework sequences can be obtained from public DNA databases or published references that include germline antibody gene sequences.
- the germline DNA sequences of the human heavy and light chain variable region genes can be found in the "VBase" human germline sequence database.
- monoclonal antibodies has gone through four stages, namely: murine monoclonal antibodies, chimeric monoclonal antibodies, humanized monoclonal antibodies and fully human monoclonal antibodies.
- the antibodies or ligands described herein may be fully human monoclonal antibodies.
- Related technologies for the preparation of fully human antibodies include: human hybridoma technology, EBV transformation of B lymphocytes, phage display technology, transgenic mouse antibody preparation technology, and single B cell antibody preparation technology.
- CDR generally refers to one of the six hypervariable regions within the variable domain of an antibody that primarily contribute to antigen binding.
- 6 CDRs are provided by Kabat E.A. et al., (1991) Sequences of proteins of immunological interest. NIH Publication 91-3242), Chothia et al., “Canonical Structures For the Hypervariable Regions of Immunoglobulins, "J. Mol. Biol. 196:901 (1987); and MacCallum et al., “Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography,” J. Mol. Biol. 262:732 (1996)).
- CDR L1, CDR L2, CDR L3 or L1, L2, L3 the Kabat definition of CDRs can be applied to CDR1, CDR2 and CDR3 (CDR L1, CDR L2, CDR L3 or L1, L2, L3) of the light chain variable domains, as well as the heavy chain variable domains of CDR1, CDR2 and CDR3 (CDR H1, CDR H2, CDR H3 or H1, H2, H3).
- methylene generally refers to a residue derived from a group of 1 carbon atom by removing two hydrogen atoms. Methylene groups can be substituted or unsubstituted, substituted or unsubstituted.
- alkylene generally refers to a saturated straight or branched aliphatic hydrocarbon group having 2 residues derived by removing two hydrogen atoms from the same or two different carbon atoms of the parent alkane, which It may be a straight or branched chain group containing from 1 to 20 carbon atoms, eg, an alkylene group containing from 1 to 12 carbon atoms, eg, containing from 1 to 6 carbon atoms.
- Non-limiting examples of alkylene groups include, but are not limited to, methylene ( -CH2- ), 1,1-ethylene (-CH( CH3 )-), 1,2-ethylene ( -CH2) CH 2 )-, 1,1-propylene (-CH(CH 2 CH 3 )-), 1,2-propylene (-CH 2 CH(CH 3 )-), 1,3-propylene ( -CH2CH2CH2- ), 1,4 - Butylene ( -CH2CH2CH2CH2- ) and 1,5 - Butylene ( -CH2CH2CH2CH2CH2- ) Wait.
- Alkylene may be substituted or unsubstituted, substituted or non-substituted, for example when substituted, substituents may be substituted at any available point of attachment, preferably independently optionally selected from alkanes group, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy substituted by one or more substituents in the group, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio and oxo, such as hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH2 , -C(O)H, -CO2H , -C(O)C(O)H, -C(O) CH2
- arylene generally refers to a residue having two residues derived by removing two hydrogen atoms from the same carbon atom or two different carbon atoms of an aromatic ring.
- aromatic ring may refer to a 6- to 14-membered all-carbon monocyclic or fused polycyclic ring (ie, rings that share adjacent pairs of carbon atoms) having a conjugated pi-electron system, and may be 6 to 10 membered, such as benzene and Naphthalene.
- the aromatic ring can be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring linked to the parent structure is an aryl ring.
- Aryl may be substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkoxy, alkane Thio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio , and heterocycloalkylthio.
- heteroarylene generally refers to a residue having two residues derived by removing two hydrogen atoms from the same carbon atom or two different carbon atoms of a heteroaromatic ring.
- heteromatic ring refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms may be selected from the group consisting of oxygen, sulfur and nitrogen.
- Heteroaryl can be 5 to 10 membered, 5 membered or 6 membered, such as furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazole Base et al.
- the heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring.
- Heteroarylene may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more of the following groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkane Oxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, Cycloalkylthio, and heterocycloalkylthio.
- the substituents are preferably one or more of the following groups independently selected from the group consisting of: alkyl, alkenyl, alkynyl, alkane Oxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl,
- heterocyclylene generally refers to stable non-aromatic 3- to 7-membered monocyclic structures, fused 7- to 10-membered bicyclic heterocyclic structures or bridged 6- to 10-membered monocyclic structures.
- Member bicyclic heterocyclic structures which may be either saturated or partially saturated, and which, in addition to carbon atoms, contain one or more heteroatoms, wherein the heteroatoms may be selected from the following groups : oxygen, sulfur and nitrogen. For example, it contains 1-4 heteroatoms as defined above.
- nitrogen may include nitrogen that has undergone a substitution reaction.
- Heterocyclylene groups can be substituted or unsubstituted.
- carbocyclylene generally refers to a residue having two residues derived by removing two hydrogen atoms from the same carbon atom or two different carbon atoms of a carbocyclic ring.
- carrier generally refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon, the carbocycle contains 3 to 20 carbon atoms, may contain 3 to 12 carbon atoms, may contain 3 to 10 carbon atoms, may Contains 3 to 8 carbon atoms.
- Non-limiting examples of monocyclic carbocycles include cyclopropane, cyclobutane, cyclopentane, cyclopentene, cyclohexane, cyclohexene, cyclohexadiene, cycloheptane, cycloheptatriene, cyclooctane etc.; polycyclic carbocycles may include spiro, fused and bridged carbocycles. Carbocyclylene can be substituted or unsubstituted.
- partially unsaturated generally refers to a cyclic structure containing at least one double or triple bond between the ring molecules.
- the term “partially unsaturated” encompasses cyclic structures with multiple unsaturations, but is not intended to include aromatic or heteroaromatic rings as defined herein.
- the term “unsaturated” means that the moiety has one or more degrees of unsaturation.
- halogen generally refers to fluorine, chlorine, bromine, iodine, and may be, for example, fluorine, chlorine.
- aliphatic group generally refers to straight-chain, branched or cyclic hydrocarbons having 1 to 12 carbon atoms, either fully saturated; or with one or Multiple unsaturated units, but the unsaturated units are not aromatic groups.
- suitable aliphatic groups may include substituted or unsubstituted linear, branched or cyclic structures of alkyl, alkenyl, alkynyl, and mixtures of these groups; such as (cycloalkyl)alkyl , (cycloalkenyl)alkyl or (cycloalkyl)alkenyl.
- aliphatic groups have 1-12, 1-8, 1-6, 1-4, or 1-3 carbon atoms.
- a heterocyclic group optionally substituted with an alkyl group means that an alkyl group may, but need not, be present, and the specification may include both instances where the heterocyclic group is substituted with an alkyl group and where the heterocyclic group is not substituted with an alkyl group. situation.
- substituted generally means that one or more hydrogen atoms in a group, eg up to 5, eg 1 to 3 hydrogen atoms, independently of one another, are substituted with the corresponding number of substituents.
- Substituents are only in their possible chemical positions, and those skilled in the art can determine (either experimentally or theoretically) possible or impossible substitutions without undue effort.
- amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (eg, olefinic) bonds.
- the term 0 or more (eg, 0 or at least 1, 0 or 1, 0) methylene units "replaced” generally refers to when the structure contains 1 or more
- One or more hydrogen atoms in the group are substituted by the corresponding number of substituents.
- Substituents are only in their possible chemical positions, and those skilled in the art can determine (either experimentally or theoretically) possible or impossible substitutions without undue effort.
- amino or hydroxyl groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (eg, olefinic) bonds.
- the term "compound” generally refers to a substance having two or more different elements.
- the compound of the present application may be an organic compound.
- the compound of the present application may be a compound with a molecular weight of 500 or less, a compound with a molecular weight of 1,000 or less, or a compound with a molecular weight of 1,000 or more, or a compound of 10,000 or more and 100,000 or more. compound.
- a compound can also refer to a compound connected by chemical bonds, for example, it can be a compound in which one or more molecules with a molecular weight of less than 1000 are connected with a biological macromolecule by chemical bonds, and the biological macromolecule can be a polysaccharide, protein , nucleic acids, peptides, etc.
- the compounds of the present application can include compounds in which proteins are linked to one or more molecules with a molecular weight of less than 1000, can include compounds in which proteins are linked to one or more molecules with a molecular weight of less than 10,000, and can include proteins and one or more molecular weights. Compounds with less than 100,000 molecules linked together.
- structures described herein may also include compounds that differ only in the presence or absence of one or more isotopically enriched atoms.
- the hydrogen atom is replaced by deuterium or tritium, or the carbon atom is replaced by carbon 13 or 1 carbon 14, the compounds whose structure is consistent with the present application are all within the scope of the present application.
- the term "pharmaceutical composition” generally refers to a mixture containing one or more of the compounds described herein, or a physiologically/pharmaceutically acceptable salt or prodrug thereof, and other chemical components, as well as other Such as physiological/pharmaceutically acceptable carriers and excipients.
- the pharmaceutical composition can facilitate the administration to the organism, facilitate the absorption of the active ingredient and then exert the biological activity.
- the preparation of conventional pharmaceutical compositions can be found in the Chinese Pharmacopoeia.
- the term "pharmaceutically acceptable salt” or “pharmaceutically acceptable salt” generally refers to a salt of a compound or ligand-drug conjugate of the present application, or a salt of a compound described in the present application, which Such salts can be safe and/or effective when used in mammals, and can have due biological activity.
- the antibody-antibody drug conjugate compounds of the present application can form salts with acids, non-pharmaceutically acceptable salts.
- Limiting examples include: hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, citrate, acetate, succinate, ascorbate, oxalate, nitrate, pearic acid Salt, hydrogen phosphate, dihydrogen phosphate, salicylates, hydrogen citrate, tartrate, maleate, fumarate, formate, benzoate, mesylate, ethanesulfonate acid salt, benzene sulfonate, p-toluene sulfonate.
- solvate or “solvate” generally refers to the ligand-drug conjugate compound of the present application forming a pharmaceutically acceptable solvate with one or more solvent molecules, non-limiting solvent molecules Examples include water, ethanol, acetonitrile, isopropanol, DMSO, ethyl acetate.
- drug loading usually refers to the average amount of cytotoxic drug loaded on each ligand, and can also be expressed as the ratio of the amount of cytotoxic drug to antibody, and the cytotoxic drug loading can range from each ligand (Ab). ) linked 0-12, eg 1-10 cytotoxic drugs.
- the drug loading is expressed as Na , which can be the mean value of 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10 exemplarily.
- the drug loading of each ADC molecule after conjugation reaction can be characterized by conventional methods such as UV/Vis spectroscopy, mass spectrometry, ELISA assay and HPLC.
- the pharmaceutical compositions may be in the form of sterile injectable aqueous or oily suspensions for intramuscular and subcutaneous administration.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol.
- sterile fixed oils are conveniently employed as a solvent or suspending medium.
- any blended fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid can also be used in the preparation of injectables.
- the term "about” generally refers to a range of 0.5%-10% above or below the specified value, such as 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10%.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable compound thereof Salts for use, wherein the compound may comprise the structure of formula (I-A):
- L 2 can be -(C(R 3a )(R 3b )) m -R, and m can be selected from an integer of 1 or more;
- L 1 can be -(C(R 5a )(R 5b )) n -, and n can be selected from an integer of 1 or more;
- -Cy- may be selected from the group consisting of: 6- to 10-membered arylene, 5- to 8-membered heteroarylene, 3- to 10-membered heterocyclylene, and 3- to 10-membered saturated or partially unsaturated carbocyclic ring group, wherein the -Cy- is unsubstituted or each independently may be substituted by 1 or more substituents R 7 ;
- each of R 3a , R 3b , R 4 , R 5a , R 5b , R 6 can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N (R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O) R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R) SO 2 R, or a C 1-6 aliphatic group which may be optionally substituted by R, or R 3a and R 5a , R 4 and R 5a , R 3a and R 6 , or R 4 and R 6 are each independently any optionally substitute
- each R 2 , R 7 , R 8 can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R , -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R , or can be any of R optionally substituted C 1-6 aliphatic groups;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (I-A):
- L 2 can be -(C(R 3a )(R 3b )) m -R, and m can be selected from an integer of 1 or more;
- L 1 can be -(C(R 5a )(R 5b )) n -, and n can be selected from an integer of 1 or more;
- -Cy- may be selected from the group consisting of: 6- to 10-membered arylene, 5- to 8-membered heteroarylene, 3- to 10-membered heterocyclylene, and 3- to 10-membered saturated or partially unsaturated carbocyclic ring group, wherein the -Cy- is unsubstituted or each independently may be substituted by 1 or more substituents R 7 ;
- each of R 3a , R 3b , R 4 , R 5a , R 5b , R 6 can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N (R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O) R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R) SO 2 R, or a C 1-6 aliphatic group that may be optionally substituted by R;
- each R 2 , R 7 , R 8 can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R , -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R , or can be any of R optionally substituted C 1-6 aliphatic groups;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or A pharmaceutically acceptable salt thereof, wherein the compound may comprise a structure represented by formula (I-A),
- R 3a and R 5a , R 4 and R 5a , R 3a and R 6 , or R 4 and R 6 each independently optionally together with the atoms between them, can form Ring B, which can Selected from the group consisting of 5- to 8-membered heteroarylene, and 3- to 10-membered saturated or partially unsaturated heterocyclylene, wherein the ring B is unsubstituted or may be substituted by more than 1 substituent R Substituted, each R 3a , R 3b , R 4 , R 5a , R 5b , R 6 can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, - N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O )
- Ring B which can be selected from the group consisting of 5- to 8-membered heteroarylene, and 3- to 10-membered saturated or partially unsaturated
- each of R 3b , R 4 , R 5b , R 6 may independently be hydrogen, protium, deuterium , Tritium, Halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O) R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N ( R a )(
- Ring B which can be selected from the group consisting of 5- to 8-membered heteroarylene, and 3- to 10-membered saturated or partially unsaturated
- each of R 3a , R 3b , R 5b , R 6 can be independently hydrogen, protium, deuterium , Tritium, Halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O) R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N ( R a )(
- Ring B which can be selected from the group consisting of 5- to 8-membered heteroarylene, and 3- to 10-membered saturated or partially unsaturated
- each of R 3b , R 4 , R 5a , R 5b may independently be hydrogen, protium, deuterium , Tritium, Halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O) R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N ( R a )
- Ring B which can be selected from the group consisting of 5- to 8 -membered heteroarylene, and 3- to 10-membered A saturated or partially unsaturated heterocyclylene group, wherein the ring B is unsubstituted or may be substituted by one or more substituents R 8 , each of which R 3a , R 3b , R 5a , R 5b independently may be is hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C( O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ) , -SO
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (I-A):
- R 1 can be -O-
- L 2 may be -(C(R 3a )(R 3b )) m -R, and m may be selected from an integer from 1 to 3;
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from an integer from 2 to 4;
- each of R 3a , R 3b , R 5a , R 5b , R 6 can each independently be hydrogen, halogen, or a C 1-6 aliphatic group that can be optionally substituted by R, or R 3a and R 5a and their Atoms in between can form Ring B, which can be selected from a 5-membered saturated heterocyclylene, wherein said Ring B is unsubstituted,
- R can be hydrogen or halogen.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (I-A):
- R 1 can be -O-
- L 2 may be -(C(R 3a )(R 3b )) m -R, and m may be an integer selected from 1 or 2;
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from an integer of 2 or 3;
- 0 or 1 methylene unit of L 1 can be replaced by -C(O)-;
- each of R 3a , R 3b , R 5a , R 5b can each independently be hydrogen, or R 3a and R 5a together with the atoms between them can form a ring B, which can be selected from 5-membered saturated Heterocyclylene having 1 nitrogen heteroatom, wherein said Ring B is unsubstituted,
- R can be hydrogen
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (I-A):
- R 1 can be -O-
- L 2 may be -(C(R 3a )(R 3b )) m -R, and m may be an integer selected from 1 or 2;
- L 1 may be -(C(R 5a )(R 5b )) 2 -;
- each of R 3a , R 3b , R 5a , R 5b can each independently be hydrogen, or R 3a and R 5a together with the atoms between them can form a ring B, which can be selected from 5-membered saturated Heterocyclylene having 1 nitrogen heteroatom, wherein said Ring B is unsubstituted,
- R can be hydrogen
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or A pharmaceutically acceptable salt thereof, wherein the compound may comprise the structure of the following group:
- the present application provides a compound or its tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the compound may comprise a structure represented by formula (II-A):
- X 1 can be selected from the group consisting of N, P, and saturated or unsaturated C, when X 1 can be saturated C, the X 1 can be substituted by R n ;
- the structure represented by the formula (II-A) is connected with other molecular moieties;
- ring A When X 1 may be saturated C, ring A may be selected from the group consisting of a 3- to 10-membered saturated or partially unsaturated heterocyclyl, and a 3- to 10-membered saturated or partially unsaturated carbocyclyl, wherein The ring A may be substituted by 0 or more substituents R 1a ;
- Ring A can be selected from the group consisting of: 6- to 10-membered aryl, 5- to 8-membered heteroaryl, 3- to 10-membered partially unsaturated heterocyclyl, and 3 to a 10-membered partially unsaturated carbocyclyl, wherein the ring A may be substituted with 0 or more substituents R 1b ;
- Ring A can be selected from the group consisting of 5- to 8-membered heteroaryl, and 3- to 10-membered saturated or partially unsaturated heterocyclyl, wherein Ring A can be Substituted by 0 or more substituents R 1c ;
- Ring A can be selected from the group consisting of 6- to 10-membered aryl, 5- to 8-membered heteroaryl, and 3- to 10-membered saturated or partially unsaturated carbocyclyl, said Ring A can be separated by p L 2 is substituted, and the L 2 cannot be R n ;
- Ring A when Ring A may be a 3- to 10-membered saturated or partially unsaturated heterocyclic group, the Ring A may be substituted with p L 2 , or the Ring A may contain q ring-forming heteroatoms X 2 And the X 2 is used to connect the structure represented by the formula (II-A) with other molecular moieties;
- X 2 can be selected from the following group: N, and P;
- L 2 can be -R 2 -L 3 -, and the R 2 is used to connect the structure represented by the formula (II-A) with other molecular moieties;
- each of R 1a , R 1b , R 1c , R 2a , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), - OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that may be optionally substituted by R;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- n and n can each independently be selected from an integer of 0 or more, and p and q can each independently be selected from an integer of 1 or more.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ax):
- X 1 may be saturated C, and X 1 may be substituted by R n ;
- Ring A may be selected from the group consisting of a 3- to 10-membered saturated or partially unsaturated heterocyclyl, and a 3- to 10-membered saturated or partially unsaturated carbocyclyl, wherein the ring A may be composed of 0 or 1 more than one substituent R 1a is substituted;
- the ring A can be substituted by p L 2 , p can be selected from an integer of 1 or more, and the L 2 cannot be R n ;
- L 2 can be -R 2 -L 3 -;
- L 3 may be -(C(R 3a )(R 3b )) m -, and m may be selected from an integer of 0 or more,
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from an integer of 0 or more,
- each R 1a , R 2a , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 , R n independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O )R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O ) R, -N(R)SO 2 R, or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ay):
- X 1 may be saturated C, and X 1 may be substituted by R n ;
- Ring A may be a 3- to 10-membered saturated or partially unsaturated heterocyclic group, wherein the ring A may not be substituted or may be substituted with more than 1 substituent R 1a ;
- the ring A may contain q ring-forming heteroatoms X 2 and the X 2 is used to directly or indirectly connect a ligand; q may be selected from an integer greater than 1, and X 2 may be selected from the group consisting of: N, and P;
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from an integer of 0 or more,
- each of R 1a , R 5a , R 5b , R 6 , and R n independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a ) (R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S (O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ax):
- X 1 can be unsaturated C
- Ring A may be selected from the group consisting of 6- to 10-membered aryl, 5- to 8-membered heteroaryl, 3- to 10-membered partially unsaturated heterocyclyl, and 3- to 10-membered partially unsaturated carbocyclyl, wherein The ring A can not be substituted or can be substituted by more than 1 substituent R 1b ;
- the ring A may be substituted by p L 2 , and p may be selected from an integer of 1 or more;
- L 2 can be -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect the ligand;
- L 3 may be -(C(R 3a )(R 3b )) m -, and m may be selected from an integer of 0 or more,
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from an integer of 0 or more,
- each R 1b , R 2a , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that can be optionally substituted by R ;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ay):
- X 1 can be unsaturated C
- Ring A may be a 3- to 10-membered partially unsaturated heterocyclic group, wherein the ring A is unsubstituted or may be substituted by more than one substituent R 1b ;
- the ring A may contain q ring-forming heteroatoms X 2 and the X 2 is used to directly or indirectly connect a ligand; q may be selected from an integer greater than 1, and X 2 may be selected from the group consisting of: N, and P;
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from an integer of 0 or more,
- each R 1b , R 5a , R 5b , R 6 can independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or can be R optionally substituted C 1-6 aliphatic group;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ax):
- X 1 can be N or P
- Ring A may be selected from the group consisting of 5- to 8-membered heteroaryl, and 3- to 10-membered saturated or partially unsaturated heterocyclyl, wherein said Ring A may not be substituted or may be substituted by more than 1 substituent R 1c replaced;
- the ring A may be substituted by p L 2 , and p may be selected from an integer of 1 or more;
- L 2 can be -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect the ligand;
- L 3 may be -(C(R 3a )(R 3b )) m -, and m may be selected from an integer of 0 or more,
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from an integer of 0 or more,
- each of R 1c , R 2a , R 3a , R 3b , R 4 , R 5a , R 5b , R 6 independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that can be optionally substituted by R ;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ay):
- X 1 can be N or P
- Ring A may be a 3- to 10-membered saturated or partially unsaturated heterocyclic group, wherein the ring A may not be substituted or may be substituted with more than 1 substituent R 1c ;
- the ring A may contain q ring-forming heteroatoms X 2 and the X 2 is used to directly or indirectly connect a ligand; q may be selected from an integer greater than 1, and X 2 may be selected from the group consisting of: N, and P;
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from an integer of 0 or more,
- each R 1c , R 5a , R 5b , R 6 can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or can be R optionally substituted C 1-6 aliphatic group;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ax):
- X 1 may be saturated C, and X 1 may be substituted by R n ;
- Ring A can be selected from the group consisting of 3- to 6-membered saturated heterocyclyl, and 3- to 6-membered saturated or partially unsaturated carbocyclyl;
- p may be 1, and the L 2 may not be R n ;
- L 2 can be -R 2 -L 3 -;
- R 2 can be selected from -O-;
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from 0 or 1;
- L 1 can comprise a methylene unit
- each R 3a , R 3b , R 5a , R 5b , R n each independently can be hydrogen, halogen or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R can independently be hydrogen or halogen.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ax):
- X 1 can be saturated C and said X 1 is attached to R n , which can be H;
- Ring A may be selected from the group consisting of a 5-membered saturated heterocyclyl group having 1 nitrogen heteroatom, and a 4- to 6-membered saturated carbocyclyl group;
- the p may be 1;
- L 2 can be -R 2 -L 3 -, and the L 3 is directly connected to the ring A;
- L 3 can be -(C(R 3a )(R 3b )) m -, and m can be 0 or 2;
- R 2 can be -O-
- L 1 can be -C(O)-
- each of R 3a , R 3b can independently be hydrogen.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ay):
- X 1 may be saturated C, and X 1 may be substituted by R n ;
- Ring A can be a 3- to 6-membered saturated heterocyclyl
- the ring A may contain 1 ring-forming heteroatom N and the N is used to directly or indirectly attach a ligand;
- L 1 may be -(C(R 5a )(R 5b )) n -, and n may be selected from 0 or 1;
- each of R 5a , R 5b , R n independently can be hydrogen, halogen or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R can independently be hydrogen or halogen.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ay):
- X 1 may be saturated C, and X 1 may be substituted with H;
- Ring A may be a 5-membered saturated heterocyclic group with 1 N heteroatom
- the ring A may contain 1 ring-forming heteroatom N and the N is used to directly or indirectly attach a ligand;
- L 1 may be -C(O)-.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ax):
- X 1 can be unsaturated C
- Ring A may be selected from the group consisting of 6-membered aryl, 5- to 8-membered heteroaryl, 3- to 10-membered partially unsaturated heterocyclyl, and 3- to 10-membered partially unsaturated carbocyclyl, wherein the ring A is not substituted or can be independently substituted by 1 substituent R 1b ;
- the p may be 1;
- L 2 can be -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect the ligand;
- L 3 may be -C(R 3a )(R 3b )-;
- R 2 can be selected from -O-, -(R 2a )N-, or -S-;
- L 1 can be -C(R 5a )(R 5b )-;
- each of R 1b , R 2a , R 3a , R 3b , R 5a , R 5b can each independently be hydrogen, halogen, or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R can independently be hydrogen or halogen.
- the compound may comprise the structure of formula (II-Ax):
- X 1 can be unsaturated C
- Ring A can be selected from the group consisting of 6-membered aryl, and 5- to 8-membered heteroaryl;
- the p may be 1;
- L 2 can be -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect the ligand;
- L 3 may be -C(R 3a )(R 3b )-;
- R 2 can be selected from -O-, -(R 2a )N-, or -S-;
- L 1 can be -C(R 5a )(R 5b )-;
- each of R 2a , R 3a , R 3b , R 5a , R 5b can each independently be hydrogen, halogen or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R can independently be hydrogen or halogen.
- the compound may comprise the structure of formula (II-Ax):
- X 1 can be unsaturated C
- Ring A can be a 6-membered aryl group
- the p may be 1;
- L 2 can be -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect the ligand;
- L 3 may be -C(R 3a )(R 3b )-;
- R 2 can be -O-
- L 1 can be -C(O)-
- each of R 3a , R 3b , R 5a , and R 5b can each independently be hydrogen or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ay):
- X 1 can be unsaturated C
- Ring A may be a 5-membered partially unsaturated heterocyclyl
- the ring A may contain 1 ring-forming heteroatom N and the N is used to directly or indirectly attach a ligand;
- L 1 can be -C(R 5a )(R 5b ),
- each R 5a , R 5b independently can be hydrogen, halogen or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R can independently be hydrogen, halogen.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ax):
- X 1 can be N
- Ring A can be a 6-membered saturated heterocyclyl
- the p may be 1;
- L 2 can be -R 2 -L 3 -, and said R 2 is used to directly or indirectly connect the ligand;
- L 3 can be -(C(R 3a )(R 3b )) m -, m can be 1 or 2,
- R 2 can be selected from the group consisting of -O-, -(R 2a )N-, and -S-;
- L 1 may be -C(R 5a )(R 5b )-,
- each of R 2a , R 3a , R 3b , R 5a , R 5b can each independently be hydrogen, halogen or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R can independently be hydrogen or halogen.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (II-Ay):
- X1 can be N
- Ring A may be a 5-membered partially unsaturated heterocyclyl
- the ring A may contain 1 ring-forming heteroatom N and the N is used to directly or indirectly attach a ligand;
- L 1 can be -C(R 5a )(R 5b ),
- each R 5a , R 5b independently can be hydrogen, halogen or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R can independently be hydrogen, halogen.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or A pharmaceutically acceptable salt thereof, which may comprise the structure of the following group:
- the present application provides a compound or its tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, wherein the compound may comprise a structure represented by formula (III-A):
- X may be selected from the group: -L 1 -C(R 1a )(R 1b )-C(O)-, -L 1 -C(R 1a )(R 1b )-C(S)-, -L 1 -L 0 -, and -L 3 -L 2 -;
- each of R 1a , R 1b , R 2 , R 2a , R 2b , R 3a , R 3b , R 4a , R 4b , R 5a , R 5b , R 6 , R 7a , R 7b , R 8 can be independently is hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C( O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ) , -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that may
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- n can be selected from an integer greater than 1;
- R 1 can be -O- or -HN-
- X can be -L 1 -CH 2 -C(O)-, wherein when L 1 can contain a methylene unit, more than one L 1
- R 1 can be -O-
- X can be -L 3 -C(O)-
- 1 methylene unit of L 3 can be replaced by -NR 8
- R 8 cannot be -CH 2 -CH 2 - NH 2 ;
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be selected from the group consisting of -O-, -(R 2 )N-, and -S-;
- X may be -L 1 -C(R 1a )(R 1b )-C(S)-;
- L 1 may be -(C(R 3a )(R 3b )) m -, and m may be selected from an integer greater than or equal to 0;
- R 2 can be halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O )R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N (R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that may be optionally substituted by R;
- each of R 1a , R 1b , R 3a , R 3b , R 4b can independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a ) (R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S (O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -S- or -(R 2 )N-;
- X may be -L 1 -C(R 1a )(R 1b )-C(O)-;
- L 1 may be -(C(R 3a )(R 3b )) m -, and m may be selected from an integer greater than or equal to 0;
- R 2 can be halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O )R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N (R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that may be optionally substituted by R;
- each of R 1a , R 1b , R 3a , R 3b , R 4b can independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a ) (R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R, -S (O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O- or -HN-
- X can be -L 1 -CH 2 -C(O)-;
- L 1 can be -(C(R 3a )(R 3b )) m -, and m can be selected from an integer of 1 or more;
- each R 3a , R 3b , R 4b can independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), - C(O)R, -CO2R, -C (O)C(O)R, -C(O) CH2C (O)R, -S(O)R, -S(O ) 2R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or optionally by R Substituted C 1-6 aliphatic groups;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O- or -HN-
- X can be -L 1 -CH 2 -C(O)-;
- L 1 may be -(C(R 3a )(R 3b )) m -, and m may be selected from an integer greater than or equal to 0;
- each R 3a , R 3b , R 4b can independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), - C(O)R, -CO2R, -C (O)C(O)R, -C(O) CH2C (O)R, -S(O)R, -S(O ) 2R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or optionally by R Substituted C 1-6 aliphatic groups;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O-, -S- or -(R 2 )N-,
- X can be -L 1 -L 0 -;
- L 1 may be -(C(R 3a )(R 3b )) m -, and m may be selected from an integer greater than or equal to 0;
- R 2 can be halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O )R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N (R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that may be optionally substituted by R;
- each R 2a , R 2b , R 3a , R 3b , R 4a , R 4b can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N( R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R , -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -HN-
- X can be -L 1 -L 0 -;
- L 1 can be -(C(R 3a )(R 3b )) m -, m can be selected from an integer greater than or equal to 0, and each R 3a , R 3b may not be hydrogen at the same time;
- each R 2a , R 2b , R 3a , R 3b , R 4a , R 4b can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N( R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R , -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R1 may be -S- or - (R2 ) N-, or R1 may be -O- and L2 may not be -C (O) - , or R1 may be -NH- and L2 may not be- C(O)-;
- L 3 can be -(C(R 7a )(R 7b )) n -, and n can be selected from an integer of 1 or more;
- R 2 can be halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O )R, -C(O)CH 2 C(O)R, -S(O)R, -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N (R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that may be optionally substituted by R;
- each R 5a , R 5b , R 6 , R 7a , R 7b , R 8 can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N( R a )(R b ), -C(O)R, -CO 2 R, -C(O)C(O)R, -C(O)CH 2 C(O)R, -S(O)R , -S(O) 2 R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or a C 1-6 aliphatic group that can be optionally substituted by R;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O-
- X can be -L 3 -L 2 -,
- L 2 can be -C(O)-
- L 3 may be -(C(R 7a )(R 7b )) n -, and n may be selected from an integer greater than or equal to 0;
- each R 7a , R 7b , R 8 can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), - C(O)R, -CO2R, -C (O)C(O)R, -C(O) CH2C (O)R, -S(O)R, -S(O ) 2R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or optionally by R Substituted C 1-6 aliphatic groups;
- R, R a , R b can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H , -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group,
- R 8 cannot be a C 1-6 aliphatic group that can be substituted by -NH 2 .
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -HN-
- X can be -L 3 -L 2 -;
- L 2 can be -C(O)-
- L 3 can be -(C(R 7a )(R 7b )) n -, and n can be selected from an integer of 1 or more;
- each R 7a , R 7b , R 8 can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR, -SR, -N(R a )(R b ), - C(O)R, -CO2R, -C (O)C(O)R, -C(O) CH2C (O)R, -S(O)R, -S(O ) 2R, -C(O)N(R a )(R b ), -SO 2 N(R a )(R b ), -OC(O)R, -N(R)SO 2 R, or optionally by R Substituted C 1-6 aliphatic groups;
- each R, R a , R b independently can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 may be -O-, -S- or -(R 2 )N-;
- X may be -L 1 -C(R 1a )(R 1b )-C(S)-;
- L 1 may be -(C(R 3a )(R 3b )) m -, and m may be 0, 1 or 2;
- each of R 1a , R 1b , R 2 , R 3a , R 3b can each independently be hydrogen or a C 1-6 aliphatic group optionally substituted by R;
- each R can be hydrogen
- the compound may comprise the structure of formula (III-A):
- R 1 can be -O-
- X may be -L 1 -C(R 1a )(R 1b )-C(S)-;
- L 1 can be -(CH 2 ) m -, and m can be 1 or 2;
- each R 1a , R 1b independently can be hydrogen or a C 1-6 aliphatic group optionally substituted by R;
- each R can be hydrogen
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -S- or -(R 2 )N-;
- X may be -L 1 -C(R 1a )(R 1b )-C(O)-;
- L 1 can be -(C(R 3a )(R 3b )) m -, m can be 0, 1 or 2,
- R 2 can be a C 1-6 aliphatic group
- each of R 1a , R 1b , R 3a , and R 3b can each independently be hydrogen or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -S- or -(R 2 )N-;
- X may be -L 1 -C(R 1a )(R 1b )-C(O)-;
- L 1 can be -(C(R 3a )(R 3b )) m -, and m can be 1 or 2;
- R 2 can be a C 1-6 aliphatic group
- each of R 1a , R 1b , R 3a , and R 3b can each independently be hydrogen or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -S- or -(R 2 )N-;
- X may be -L 1 -C(R 1a )(R 1b )-C(O)-;
- L 1 can be -(C(R 3a )(R 3b )) m -, and when m can be 0, 1 or 2,
- R 2 can be a C 1-6 aliphatic group
- R 1a , R 1b , R 3a , and R 3b can independently be hydrogen or C 1-6 aliphatic group
- X can be -L 1 -CH 2 -C(O)-;
- L 1 can be -(C(R 3a )(R 3b )) 2 -;
- each R 3a , R 3b can be hydrogen, or C 1-6 aliphatic group independently;
- Each of R 3a , R 3b may not be hydrogen at the same time, or 1 methylene unit of L 1 may be replaced by -C(O)-;
- each R 3a , R 3b can each independently be hydrogen, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O-
- X can be -L 1 -CH 2 -C(O)-;
- L 1 may be -(C(R 3a )(R 3b )) 2 -;
- each R 3a , R 3b can be hydrogen, or C 1-6 aliphatic group independently;
- Each of R 3a , R 3b may not be hydrogen at the same time, or 1 methylene unit of L 1 may be replaced by -C(O)-;
- each R 3a , R 3b can each independently be hydrogen, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -S- or -(R 2 )N-;
- X may be -L 1 -C(R 1a )(R 1b )-C(O)-;
- L 1 can be -(C(R 3a )(R 3b )) m -, and when m can be 0, 1 or 2,
- R 2 can be a C 1-6 aliphatic group
- R 1a , R 1b , R 3a , and R 3b can independently be hydrogen or C 1-6 aliphatic group
- L 1 may be -C(R 3a )(R 3b )-, and in each -C(R 3a )(R 3b )-, R 3a and R 3b may be hydrogen at different times;
- each of R 3a , R 3b may independently be hydrogen or C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O-
- X can be -L 1 -CH 2 -C(O)-;
- L 1 may be -(C(R 3a )(R 3b )) 2 -;
- each R 3a , R 3b can be hydrogen, or C 1-6 aliphatic group independently;
- R 3a , R 3b may not be hydrogen at the same time, or 1 methylene unit of L 1 may be replaced by -C(O)-;
- each R 3a , R 3b can each independently be hydrogen, or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O-
- X can be -L 1 -CH 2 -C(O)-;
- L 1 can be -(CH 2 ) 2 -;
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O-
- X can be -L 1 -CH 2 -C(O)-;
- L 1 may be -(C(R 3a )(R 3b )) m -, m may be selected from an integer from 1 to 5, and in each -C(R 3a )(R 3b )- R 3a , R 3b are not At the same time, it can be hydrogen;
- each R 3a , R 3b independently can be hydrogen, halogen or a C 1-6 aliphatic group optionally substituted by R;
- each R can be hydrogen or halogen.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O-
- X can be -L 1 -CH 2 -C(O)-;
- L 1 may be -C(R 3a )(R 3b )-, and R 3a and R 3b may not be hydrogen at the same time;
- each of R 3a , R 3b may independently be hydrogen or C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O- or -(R 2 )N-
- X can be -L 1 -L 0 -;
- L 1 may be -(CH 2 ) m -, and m may be selected from an integer from 0 to 2;
- R 2 may be a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -NH-
- X can be -L 1 -L 0 -;
- L 1 may be -(CH 2 ) m -, and m may be selected from an integer from 0 to 2;
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -S-, or -(R 2 )N-;
- X can be -L 3 -L 2 -,
- L 2 can be -C(O)-
- L 3 can be -(CH 2 ) n -, and n can be 4 or 5;
- One methylene unit of L 3 can be replaced by -NR 8 -, -O-, -S- or -SO-;
- R 2 may be a C 1-6 aliphatic group.
- R 1 can be -S- or -(R 2 )N-;
- X can be -L 3 -L 2 -,
- L 2 can be -C(O)-
- L 3 can be -(CH 2 ) n -, and n can be 4 or 5;
- R 2 may be a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O-
- X can be -L 3 -L 2 -,
- L 2 can be -C(O)-
- L 3 can be -(C(R 7a )(R 7b )) n -, and n can be 4 or 5;
- each of R 7a , R 7b , and R 8 can each independently be hydrogen, or a C 1-6 aliphatic group.
- R 1 can be -O-
- X can be -L 3 -L 2 -,
- L 2 can be -C(O)-
- L 3 may be -(C(R 7a )(R 7b )) 4 -;
- 1 methylene unit of L 3 can be replaced by -NR 8 - or -O-;
- each of R 7a , R 7b , and R 8 can each independently be hydrogen or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -O-
- X can be -L 3 -L 2 -,
- L 2 can be -C(O)-
- L 3 may be -(C(R 7a )(R 7b )) 4 -;
- each of R 7a , R 7b , and R 8 can each independently be hydrogen or a C 1-6 aliphatic group.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or Its pharmaceutically acceptable salt, wherein the compound may comprise the structure represented by formula (III-A):
- R 1 can be -NH-
- X can be -L 3 -L 2 -,
- L 2 can be -C(O)-
- L 3 can be -(CH 2 ) n -, and n can be 4 or 5;
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a mixture thereof, or A pharmaceutically acceptable salt thereof, wherein the compound may comprise the structure of the following group:
- R 2 can be a C 1-6 aliphatic group that can be optionally substituted by R, and R can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or a C 1-6 aliphatic group; or wherein R 2 can be halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O )H, or
- R 2 can be a group that can be replaced by one or more of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH2 , -OC(O)H, -N(H) SO2H , or methyl optionally substituted with a C1-6 aliphatic group.
- R 2 can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O )C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , - OC(O)H, -N(H) SO2H , or C1-6 aliphatic optionally substituted ethyl.
- R 2 can be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O )C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , - OC(O)H, -N(H) SO2H , or C1-6 aliphatic optionally substituted propyl.
- the application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a A pharmaceutically acceptable salt, which may comprise the structure represented by formula (I-B):
- X a can be the nitrogen generated by the removal of two hydrogen atoms from the amino group of the cytotoxic drug
- the L can be -L a -L b -L c -;
- the -L a - may be selected from the following group:
- W can be -(C(R wa )(R wb )) wn -
- Y can be -(OCH 2 CH 2 ) yn -O yp -
- Z can be -(C(R za )(R zb ) ) zn ;
- wn can be selected from an integer greater than 0,
- yn can be selected from an integer greater than 0, and yp can be 0 or 1;
- zn can be selected from an integer greater than 0,
- -Cyr- may be selected from the group consisting of: 6- to 10-membered arylene, 5- to 8-membered heteroarylene, 3- to 10-membered heterocyclylene, and 3- to 10-membered saturated or partially unsaturated carbocyclic ring base, wherein the -Cyr- is unsubstituted or independently may be substituted by more than 1 substituent R cx ;
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR r , - SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O )R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), - OC(O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic
- each R r , R ra , R rb can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the -L c - may be selected from the following group:
- R L1 and R L2 can each independently be selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, and C 1-6 aliphatic groups;
- R 1 , L 1 , L 2 are as defined in any one of formula (IA) in the embodiments of the first aspect.
- the present application provides a compound or its tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, Or its pharmaceutically acceptable salt, it can comprise the structure shown in formula (II-Bx) or formula (II-By):
- X a can be the nitrogen generated by the removal of two hydrogen atoms from the amino group of the cytotoxic drug
- the L can be -L a -L b -L c -;
- the -L a - may be selected from the following group:
- W can be -(C(R wa )(R wb )) wn -
- Y can be -(OCH 2 CH 2 ) yn -O yp -
- Z can be -(C(R za )(R zb ) ) zn ;
- wn can be selected from an integer greater than 0,
- yn can be selected from an integer greater than 0, and yp can be 0 or 1;
- zn can be selected from an integer greater than 0,
- -Cyr- may be selected from the group consisting of: 6- to 10-membered arylene, 5- to 8-membered heteroarylene, 3- to 10-membered heterocyclylene, and 3- to 10-membered saturated or partially unsaturated carbocyclic ring base, wherein the -Cyr- is unsubstituted or independently may be substituted by more than 1 substituent R cx ;
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR r , - SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O )R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), - OC(O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic
- each R r , R ra , R rb can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the -L c - may be selected from the following group:
- R L1 and R L2 can each independently be selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, and C 1-6 aliphatic groups;
- L 2 , p, Ring A, X 1 , L 1 are as defined in any of the embodiments of the first aspect of formula (II-Ax);
- X 2 , q, ring A, X 1 , L 1 are as defined in any of the embodiments of the first aspect of formula (II-Ay).
- the present application provides a compound or its tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, Or its pharmaceutically acceptable salt, it can comprise the structure shown in formula (III-B):
- X a can be the nitrogen generated by the removal of two hydrogen atoms from the amino group of the cytotoxic drug
- the L can be -L a -L b -L c -;
- the -L a - may be selected from the following group:
- W can be -(C(R wa )(R wb )) wn -
- Y can be -(OCH 2 CH 2 ) yn -O yp
- Z can be -(C(R za )(R zb )) zn ,;
- wn can be selected from an integer greater than 0,
- yn can be selected from an integer greater than 0, and yp can be 0 or 1;
- zn can be selected from an integer greater than 0,
- -Cyr- may be selected from the group consisting of: 6- to 10-membered arylene, 5- to 8-membered heteroarylene, 3- to 10-membered heterocyclylene, and 3- to 10-membered saturated or partially unsaturated carbocyclic ring base, wherein the -Cyr- is unsubstituted or independently may be substituted by more than 1 substituent R cx ;
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR r , - SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O )R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), - OC(O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic
- each R r , R ra , R rb can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the -L c - may be selected from the following group:
- R L1 and R L2 can each independently be selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, - CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, and C 1-6 aliphatic groups;
- R 1 , X are as defined in any one of formula (III-A) in the embodiments of the first aspect.
- wn may be selected from an integer from 2 to 6
- 0 or 1 methylene unit of W may each independently be replaced by -Cyr-, -N( Rwx )C(O)- , -C(O)N( Rwx )-, -C(O)-, -NRwx- , or -O- instead.
- one methylene unit of W can each independently be replaced by -Cyr-, -N(R wx )C(O)-, -C(O)N( R wx )-, or -C(O)- substitution.
- yn may be selected from an integer from 0 to 12, and yp may be 0 or 1.
- yn can be 0, 4 or 8 and yp can be 0 or 1.
- each of 0 or 1 methylene unit of Z may be independently -Cyr-, -N(R zx )C(O)- , -C(O)N(R zx )-, or -C(O)- substitution.
- one methylene unit of Z can each independently be replaced by -Cyr-, -N( Rzx )C(O)-, -C(O)N( Rzx )-, or -C(O)- substitution.
- -Cyr- may be selected from the group consisting of 6 to 10 membered arylene, and 3 to 10 membered saturated or partially unsaturated carbocyclylene, wherein -Cyr- is unsaturated Substituted or independently may be substituted with 1 to 3 substituents R cx .
- -Cyr- can be a 3 to 10 membered saturated carbocyclylene, wherein the -Cyr- is unsubstituted or independently substituted with 1 to 3 substituents R cx .
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR r , -SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C (O)CH 2 C(O)R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), -OC(O)R r , -N(R)SO 2 R r , or a C 1-6 alipha
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, halogen, -OR r or C 1-6 optionally substituted by R r an aliphatic group; wherein each R r can independently be hydrogen, halogen, or a C 1-6 aliphatic group.
- the -L b - represents a peptide residue consisting of 2 to 7 amino acids
- the peptide residue of -L b - may be formed from amino acids that may be selected from the group consisting of The peptide residues: phenylalanine, glycine, alanine, valine, citrulline, lysine, serine, glutamic acid, and aspartic acid.
- the -L b - represents a peptide residue composed of 2 to 4 amino acids
- the peptide residue of the -L b - may be a peptide residue that may be formed from amino acids that may be selected from the group consisting of: benzene Alanine, Glycine, Alanine, Valine, Citrulline and Lysine.
- the -L b - may be selected from the following group:
- the -L b - can be
- the -L c - may be selected from the group consisting of:
- the -Lc- may be selected from the group consisting of:
- the -L c - can be
- R L1 , R L2 can each independently be selected from the group consisting of hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO2H , -C(O)C(O)H, -C(O) CH2C (O)H, -S(O)H, -S(O ) 2H , -C (O) NH2 , -SO2NH2 , -OC(O)H, -N(H) SO2H , and C1-6 aliphatic groups.
- R L1 , R L2 can each independently be selected from the group consisting of hydrogen, halogen, -OH and C 1-6 aliphatic groups.
- -L b - may be selected from the group consisting of:
- -L b - can be selected from the following group:
- -L c - can be
- -L a -L b -L c - can be selected from the group consisting of:
- cytotoxic drug is shown in formula (EXA):
- the present application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a compound thereof.
- a pharmaceutically acceptable salt which may comprise the structure represented by formula (I-C):
- L can be -L a -L b -L c -, and L a , L b , and L c are as defined in any formula (IB) in the embodiments of the second aspect;
- R 1 , L 1 , L 2 are as defined in any one of formula (IA) in the embodiments of the first aspect.
- the present application provides a compound or its tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, Or its pharmaceutically acceptable salt, it can comprise the structure shown in formula (II-Cx) or formula (II-Cy):
- L can be -L a -L b -L c -, and L a , L b , and L c are as defined in any of the formulas (II-Bx) in the embodiments of the second aspect;
- L 2 , p, Ring A, X 1 , L 1 are as defined in any of the embodiments of the first aspect of formula (II-Ax);
- X 2 , q, ring A, X 1 , L 1 are as defined in any of the embodiments of the first aspect of formula (II-Ay).
- the present application provides a compound or its tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, Or its pharmaceutically acceptable salt, it can comprise the structure shown in formula (III-C):
- L can be -L a -L b -L c -, and L a , L b , and L c are as defined in any one of the formulae (III-B) in the embodiments of the second aspect;
- R 1 , X are as defined in any one of formula (III-A) in the embodiments of the first aspect.
- the present application provides a compound or a tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a compound thereof.
- a pharmaceutically acceptable salt which may comprise the structure shown in formula (I-D):
- Ab can be a ligand, and the average number of connections Na can be an integer or decimal from 1 to 10;
- L may be -L a -L b -L c -, L a , L b , L c as defined in any of the embodiments of the second aspect of formula (IB);
- R 1 , L 1 , L 2 are as defined in any one of formula (IA) in the embodiments of the first aspect.
- the present application provides a compound or its tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, which may comprise a structure represented by formula (II-Dx) or formula (II-Dy)
- Ab can be a ligand, and the average number of connections Na can be an integer or decimal from 1 to 10;
- L may be -L a -L b -L c -, L a , L b , L c as defined in any one of formulae (II-Bx) in the embodiments of the second aspect;
- L 2 , Ring A, X 1 , L 1 are as defined in any of the embodiments of the first aspect of formula (II-Ax);
- the present application provides a compound or its tautomer, meso, racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, which may comprise the structure represented by formula (III-D)
- Ab can be a ligand, and the average number of connections Na can be an integer or decimal from 1 to 10;
- L may be -L a -L b -L c -, L a , L b , L c as defined in any one of the embodiments of the second aspect of formula (III-B);
- R 1 , X are as defined in any one of formula (III-A) in the embodiments of the first aspect.
- the ligand Ab can be an antibody or an antigen-binding fragment thereof.
- the ligand Ab can be selected from the group consisting of chimeric antibodies, humanized antibodies, and fully human antibodies.
- the ligand Ab targets the following group: HER2, HER3, B7H3, TROP2, Claudin 18.2, CD30, CD33, CD70 and EGFR.
- the ligand Ab targets the following group:
- the antibody may be an antibody targeting the following targets: 5T4, AGS-16, ANGPTL4, ApoE, CD19, CTGF, CXCR5, FGF2, MCPT8, MFI2, MS4A7, NCA, Sema5b, SLITRK6, STC2, TGF, 0772P, 5T4, ACTA2, ADGRE1, AG-7, AIF1, AKR1C1, AKR1C2, ASLG659, Axl, B7H3, BAFF-R, BCMA, BMPR1B, BNIP3, C1QA, C1QB, CA6, CADM1, CCD79b, CCL5, CCR5, CCR7, CD1lc, CD123, CD138, CD142, CD147, CD166, CD19, CD19, CD22, CD21, CD20, CD205, CD22, CD223, CD228, CD25, CD30, CD33, CD37, CD38, CD40, CD45, CD45 (PTPRC
- the average number of connections Na may be an integer or decimal from 2 to 8.
- the average number of connections Na may be an integer or decimal from 3 to 8.
- the average number of connections Na may be an integer or decimal from 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, 8 to 9, 9 to 10 .
- the present application provides a compound represented by the general formula (I-E) or a tautomer, meso, racemate, enantiomer, diastereomer, or In the form of a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
- R 1 , L 1 , and L 2 are as defined in any one of formula (IA) in the embodiments of the first aspect.
- the present application provides a compound represented by general formula (II-E x ) or general formula (II-E y ) or its tautomer, meso, racem isomers, enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, wherein:
- L 2 , p, ring A, X 1 , L 1 are as defined in any one of the formulae (II-Ax) in the embodiments of the first aspect;
- X 2 , q, ring A, X 1 , L 1 are as defined in any of the embodiments of the first aspect of formula (II-Ay).
- the present application provides a compound represented by the general formula (III-E) or its tautomer, meso, racemate, enantiomer, non-pair An enantiomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
- R 1 , X are as defined in any one of formula (III-A) in the embodiments of the first aspect.
- the present application provides a compound represented by general formula (I-F) or its tautomer, meso, racemate, enantiomer, diastereomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
- the L x can be -L ax -L b -L c -;
- the Lax- may be selected from the following group:
- R hal can be iodine or bromine
- W can be -(C(R wa )(R wb )) wn -
- Y can be -(OCH 2 CH 2 ) yn -O yp -
- Z can be -(C(R za )(R zb ) ) zn ;
- wn can be selected from an integer greater than 0,
- yn can be selected from an integer greater than 0, and yp can be 0 or 1;
- zn can be selected from an integer greater than 0,
- -Cyr- may be selected from the group consisting of: 6- to 10-membered arylene, 5- to 8-membered heteroarylene, 3- to 10-membered heterocyclylene, and 3- to 10-membered saturated or partially unsaturated carbocyclic ring base, wherein the -Cyr- is unsubstituted or independently may be substituted by more than 1 substituent R cx ;
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR r , - SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O )R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), - OC(O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic
- each R r , R ra , R rb can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- L b , L c are as defined in any one of formula (IB) in the embodiments of the second aspect;
- R 1 , L 1 , L 2 are as defined in any one of formula (IA) in the embodiments of the first aspect.
- the present application provides a compound represented by general formula (II-F x ) or general formula (II-F y ) or its tautomer, meso, and racemate , enantiomers, diastereomers, or mixtures thereof, or pharmaceutically acceptable salts thereof, wherein:
- the L x can be -L ax -L b -L c -;
- the Lax- may be selected from the following group:
- R hal can be iodine or bromine
- W can be -(C(R wa )(R wb )) wn -
- Y can be -(OCH 2 CH 2 ) yn -O yp -
- Z can be -(C(R za )(R zb ) ) zn ;
- wn can be selected from an integer greater than 0,
- yn can be selected from an integer greater than 0, and yp can be 0 or 1;
- zn can be selected from an integer greater than 0,
- -Cyr- may be selected from the group consisting of: 6- to 10-membered arylene, 5- to 8-membered heteroarylene, 3- to 10-membered heterocyclylene, and 3- to 10-membered saturated or partially unsaturated carbocyclic ring base, wherein the -Cyr- is unsubstituted or independently may be substituted by more than 1 substituent R cx ;
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR r , - SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O )R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), - OC(O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic
- each R r , R ra , R rb can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- L b , L c are as defined in any one of the formulae (II-Bx) in the embodiments of the second aspect;
- L 2 , p, ring A, X 1 , L 1 are as defined in any one of the formulae (II-Ax) in the embodiments of the first aspect;
- X 2 , q, ring A, X 1 , L 1 are as defined in any of the embodiments of the first aspect of formula (II-Ay).
- the present application provides a compound represented by general formula (III-F) or its tautomer, meso, racemate, enantiomer, non-pair An enantiomer, or a mixture thereof, or a pharmaceutically acceptable salt thereof, wherein:
- the L x can be -L ax -L b -L c -;
- the Lax- may be selected from the following group:
- R hal can be iodine or bromine
- W can be -(C(R wa )(R wb )) wn -
- Y can be -(OCH 2 CH 2 ) yn -O yp -
- Z can be -(C(R za )(R zb ) ) zn ;
- wn can be selected from an integer greater than 0,
- yn can be selected from an integer greater than 0, and yp can be 0 or 1;
- zn can be selected from an integer greater than 0,
- -Cyr- may be selected from the group consisting of: 6- to 10-membered arylene, 5- to 8-membered heteroarylene, 3- to 10-membered heterocyclylene, and 3- to 10-membered saturated or partially unsaturated carbocyclic ring base, wherein the -Cyr- is unsubstituted or independently may be substituted by more than 1 substituent R cx ;
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR r , - SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C(O)CH 2 C(O )R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), - OC(O)R r , -N(R)SO 2 R r , or a C 1-6 aliphatic
- each R r , R ra , R rb can be independently hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OH, -SH, -NH 2 , -C(O)H, -CO 2 H, -C(O)C(O)H, -C(O)CH 2 C(O)H, -S(O)H, -S(O) 2 H, -C(O)NH 2 , -SO 2 NH 2 , -OC(O)H, -N(H)SO 2 H, or C 1-6 aliphatic group;
- L b , L c are as defined in any one of formula (III-B) in the embodiments of the second aspect;
- R 1 , X are as defined in any one of formula (III-A) in the embodiments of the first aspect.
- the Lax- may be selected from the group of:
- R hal can be iodine or bromine
- W can be -(C(R wa )(R wb )) wn -
- Y can be -(OCH 2 CH 2 ) yn -O yp -
- Z can be -(C(R za )(R zb ) ) zn .
- wn may be selected from an integer from 2 to 6
- 0 or 1 methylene unit of W may each independently be replaced by -Cyr-, -N( Rwx )C(O)- , -C(O)N( Rwx )-, -C(O)-, -NRwx- , or -O- instead.
- one methylene unit of W can each independently be replaced by -Cyr-, -N(R wx )C(O)-, -C(O)N( R wx )-, or -C(O)- substitution.
- yn may be selected from an integer from 0 to 12, and yp may be 0 or 1.
- yn can be 0, 4 or 8 and yp can be 0 or 1.
- each of 0 or 1 methylene unit of Z may be independently -Cyr-, -N(R zx )C(O)- , -C(O)N(R zx )-, or -C(O)- substitution.
- one methylene unit of Z can each independently be replaced by -Cyr-, -N( Rzx )C(O)-, -C(O)N( Rzx )-, or -C(O)- substitution.
- -Cyr- may be selected from the group consisting of 6 to 10 membered arylene, and 3 to 10 membered saturated or partially unsaturated carbocyclylene, wherein -Cyr- is unsaturated Substituted or independently may be substituted with 1 to 3 substituents R cx .
- -Cyr- can be a 3 to 10 membered saturated carbocyclylene, wherein the -Cyr- is unsubstituted or independently substituted with 1 to 3 substituents R cx .
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, protium, deuterium, tritium, halogen, -NO 2 , -CN, -OR r , -SR r , -N(R ra )(R rb ), -C(O)R r , -CO 2 R r , -C(O)C(O)R r , -C (O)CH 2 C(O)R r , -S(O)R r , -S(O) 2 R r , -C(O)N(R ra )(R rb ), -SO 2 N(R ra )(R rb ), -OC(O)R r , -N(R)SO 2 R r , or a C 1-6 alipha
- each R wa , R wb , R za , R zb , R wx , R zx , R cx can each independently be hydrogen, halogen, -OR r or C 1-6 optionally substituted by R r an aliphatic group; wherein each R r can independently be hydrogen, halogen, or a C 1-6 aliphatic group.
- Lax - can be
- Lax - Lb - Lc- can be selected from the group of:
- the compounds disclosed herein include, but are not limited to:
- the average number of connections n in the above list can be an integer or decimal from 1 to 10.
- the average number of connections n in the above list can be an integer or decimal from 2 to 8.
- the average number of connections n may be an integer from 3 to 8 or a decimal.
- the average number of connections n may be an integer or decimal from 1 to 2, 2 to 3, 3 to 4, 4 to 5, 5 to 6, 6 to 7, 7 to 8, 8 to 9, and 9 to 10.
- the compounds disclosed herein include, but are not limited to:
Abstract
Description
ADC编号 | 肿瘤抑制率% |
参照ADC-1 | 54.14 |
ADC-II-9 | 134.29 |
ADC-II-13 | 58.75 |
ADC-III-9 | 93.79 |
ADC编号 | 肿瘤抑制率% |
参照ADC-1 | 54.14 |
ADC-II-9 | 68.86 |
ADC-III-1 | 80.39 |
ADC-III-9 | 93.05 |
ADC编号 | 肿瘤抑制率% |
参照ADC-2 | 62.64 |
ADC-III-28 | 96.84 |
ADC编号 | 肿瘤抑制率% |
参照ADC-2(3mg/kg) | 33.73% |
参照ADC-2(10mg/kg) | 55.01% |
ADC-III-28(3mg/kg) | 58.74% |
ADC-III-28(3mg/kg) | 81.18% |
Claims (103)
- 一种化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述化合物包含式(II-A)所示的结构:其中X 1为饱和的C,所述X 1被R n取代;环A选自以下组:3到10元饱和的或部分不饱和的杂环基,和3到10元饱和的或部分不饱和的碳环基,其中所述环A被0个或至少1个取代基R 1a取代;当环A为3到10元饱和的或部分不饱和的碳环基时,所述环A被p个L 2取代,所述L 2不为R n;或者,当环A为3到10元饱和的或部分不饱和的杂环基时,所述环A被p个L 2取代;L 2为-R 2-L 3-,所述R 2用于直接或间接连接配体;L 3为-(C(R 3a)(R 3b)) m-,其中当L 3包含亚甲基单元时,所述L 3的0个或至少1个亚甲基单元各自独立地被-N(R 4)C(O)-、-C(O)N(R 4)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 4-、-O-、-S-、-SO-、-SO 2-、-P(R 4)-、-P(=O)(R 4)-、-N(R 4)SO 2-、-SO 2N(R 4)-、-C(=S)-、-C(=NR 4)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;R 2选自以下组:-O-,-(R 2a)N-,-S-,和-P(=O)(R 2a)-;L 1为-(C(R 5a)(R 5b)) n-,其中当L 1包含亚甲基单元时,所述L 1的0个或至少1个亚甲基单元各自独立地被-N(R 6)C(O)-、-C(O)N(R 6)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 6-、-O-、-S-、-SO-、-SO 2-、-P(R 6)-、-P(=O)(R 6)-、-N(R 6)SO 2-、-SO 2N(R 6)-、-C(=S)-、-C(=NR 6)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中每个R 1a,R 2a,R 3a,R 3b,R 4,R 5a,R 5b,R 6,R n各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、-S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m,n各自独立地选自至少为0的整数,p为至少为1的整数。
- 一种通式(II-E x)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中:其中X 1为饱和的C,所述X 1被R n取代;环A选自以下组:3到10元饱和的或部分不饱和的杂环基,和3到10元饱和的或部分不饱和的碳环基,其中所述环A被0个或至少1个取代基R 1a取代;当环A为3到10元饱和的或部分不饱和的碳环基时,所述环A被p个L 2取代,所述L 2不为R n;或者,当环A为3到10元饱和的或部分不饱和的杂环基时,所述环A被p个L 2取代;L 2为-R 2-L 3-,所述R 2用于直接或间接连接配体;L 3为-(C(R 3a)(R 3b)) m-,其中当L 3包含亚甲基单元时,所述L 3的0个或至少1个亚甲基单元各自独立地被-N(R 4)C(O)-、-C(O)N(R 4)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 4-、-O-、-S-、-SO-、-SO 2-、-P(R 4)-、-P(=O)(R 4)-、-N(R 4)SO 2-、-SO 2N(R 4)-、-C(=S)-、-C(=NR 4)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;R 2选自以下组:-O-,-(R 2a)N-,-S-,和-P(=O)(R 2a)-;L 1为-(C(R 5a)(R 5b)) n-,其中当L 1包含亚甲基单元时,所述L 1的0个或至少1个亚甲基单元各自独立地被-N(R 6)C(O)-、-C(O)N(R 6)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 6-、-O-、-S-、-SO-、-SO 2-、-P(R 6)-、-P(=O)(R 6)-、-N(R 6)SO 2-、-SO 2N(R 6)-、-C(=S)-、-C(=NR 6)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中每个R 1a,R 2a,R 3a,R 3b,R 4,R 5a,R 5b,R 6,R n各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、-S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m,n各自独立地选自至少为0的整数,p为至少为1的整数。
- 一种化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其包含式(II-C x)所示的结构:所述L为-L a-L b-L c-;所述-L a-选自以下组:其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn选自至少为0的整数,W的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR wx-、-O-、-S-、-SO-、-SO 2-、-P(R wx)-、-P(=O)(R wx)-、-N(R wx)SO 2-、-SO 2N(R wx)-、-C(=S)-、-C(=NR wx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中yn选自至少为0的整数,yp为0或1;其中zn选自至少为0的整数,Z的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR zx-、-O-、-S-、-SO-、-SO 2-、-P(R zx)-、-P(=O)(R zx)-、-N(R zx)SO 2-、-SO 2N(R zx)-、-C(=S)-、-C(=NR zx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;-Cyr-选自以下组:6到10元亚芳基、5到8元亚杂芳基、3到10元亚杂环基、和3到10元饱和的或部分不饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被至少1个的取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR r、-SR r、-N(R ra)(R rb)、-C(O)R r、-CO 2R r、-C(O)C(O)R r、-C(O)CH 2C(O)R r、-S(O)R r、-S(O) 2R r、-C(O)N(R ra)(R rb)、-SO 2N(R ra)(R rb)、-OC(O)R r、-N(R)SO 2R r、或被R r任选取代的C 1- 6脂肪族基团;其中每个R r,R ra,R rb各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;所述-L b-表示由2到7个氨基酸构成的肽残基;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、和C 1-6脂肪族基团;其中X 1为饱和的C,所述X 1被R n取代;环A选自以下组:3到10元饱和的或部分不饱和的杂环基,和3到10元饱和的或部分不饱和的碳环基,其中所述环A被0个或至少1个取代基R 1a取代;当环A为3到10元饱和的或部分不饱和的碳环基时,所述环A被p个L 2取代,所述L 2不为R n;或者,当环A为3到10元饱和的或部分不饱和的杂环基时,所述环A被p个L 2取代;L 2为-R 2-L 3-,所述R 2用于直接或间接连接配体;L 3为-(C(R 3a)(R 3b)) m-,其中当L 3包含亚甲基单元时,所述L 3的0个或至少1个亚甲基单元各自独立地被-N(R 4)C(O)-、-C(O)N(R 4)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 4-、-O-、-S-、-SO-、-SO 2-、-P(R 4)-、-P(=O)(R 4)-、-N(R 4)SO 2-、-SO 2N(R 4)-、-C(=S)-、-C(=NR 4)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;R 2选自以下组:-O-,-(R 2a)N-,-S-,和-P(=O)(R 2a)-;L 1为-(C(R 5a)(R 5b)) n-,其中当L 1包含亚甲基单元时,所述L 1的0个或至少1个亚甲基单元各自独立地被-N(R 6)C(O)-、-C(O)N(R 6)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 6-、-O-、-S-、-SO-、-SO 2-、-P(R 6)-、-P(=O)(R 6)-、-N(R 6)SO 2-、-SO 2N(R 6)-、-C(=S)-、-C(=NR 6)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中每个R 1a,R 2a,R 3a,R 3b,R 4,R 5a,R 5b,R 6,R n各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、-S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m,n各自独立地选自至少为0的整数,p为至少为1的整数。
- 一种化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其包含式(II-D x)所示的结构:其中,Ab为配体,平均连接数N a为1到10的整数或小数;所述L为-L a-L b-L c-;所述-L a-选自以下组:其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn选自至少为0的整数,W的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR wx-、-O-、-S-、-SO-、-SO 2-、-P(R wx)-、-P(=O)(R wx)-、-N(R wx)SO 2-、-SO 2N(R wx)-、-C(=S)-、-C(=NR wx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中yn选自至少为0的整数,yp为0或1;其中zn选自至少为0的整数,Z的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR zx-、-O-、-S-、-SO-、-SO 2-、-P(R zx)-、-P(=O)(R zx)-、-N(R zx)SO 2-、-SO 2N(R zx)-、-C(=S)-、-C(=NR zx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;-Cyr-选自以下组:6到10元亚芳基、5到8元亚杂芳基、3到10元亚杂环基、和3到10元饱和的或部分不饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被至少1个的取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR r、-SR r、-N(R ra)(R rb)、-C(O)R r、-CO 2R r、-C(O)C(O)R r、-C(O)CH 2C(O)R r、-S(O)R r、-S(O) 2R r、-C(O)N(R ra)(R rb)、-SO 2N(R ra)(R rb)、-OC(O)R r、-N(R)SO 2R r、或被R r任选取代的C 1- 6脂肪族基团;其中每个R r,R ra,R rb各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;所述-L b-表示由2到7个氨基酸构成的肽残基;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、和C 1-6脂肪族基团;其中X 1为饱和的C,所述X 1被R n取代;环A选自以下组:3到10元饱和的或部分不饱和的杂环基,和3到10元饱和的或部分不饱和的碳环基,其中所述环A被0个或至少1个取代基R 1a取代;当环A为3到10元饱和的或部分不饱和的碳环基时,所述环A被p个L 2取代,所述L 2不为R n;或者,当环A为3到10元饱和的或部分不饱和的杂环基时,所述环A被p个L 2取代;L 2为-R 2-L 3-,所述R 2用于直接或间接连接配体;L 3为-(C(R 3a)(R 3b)) m-,其中当L 3包含亚甲基单元时,所述L 3的0个或至少1个亚甲基单元各自独立地被-N(R 4)C(O)-、-C(O)N(R 4)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 4-、-O-、-S-、-SO-、-SO 2-、-P(R 4)-、-P(=O)(R 4)-、-N(R 4)SO 2-、-SO 2N(R 4)-、-C(=S)-、-C(=NR 4)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;R 2选自以下组:-O-,-(R 2a)N-,-S-,和-P(=O)(R 2a)-;L 1为-(C(R 5a)(R 5b)) n-,其中当L 1包含亚甲基单元时,所述L 1的0个或至少1个亚甲基单元各自独立地被-N(R 6)C(O)-、-C(O)N(R 6)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 6-、-O-、-S-、-SO-、-SO 2-、-P(R 6)-、-P(=O)(R 6)-、-N(R 6)SO 2-、-SO 2N(R 6)-、-C(=S)-、-C(=NR 6)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中每个R 1a,R 2a,R 3a,R 3b,R 4,R 5a,R 5b,R 6,R n各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、-S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m,n各自独立地选自至少为0的整数,p为至少为1的整数。
- 根据权利要求4所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述配体Ab为抗体或其抗原结合片段。
- 根据权利要求4-5中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述配体Ab选自以下组:嵌合抗体、人源化抗体和全人源抗体。
- 根据权利要求4-6中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述配体Ab靶向以下组:HER2、HER3、B7H3、TROP2、Claudin 18.2、CD30、CD33、CD70和EGFR。
- 根据权利要求3-7中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映 异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述-L a-选自以下组:其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn选自2到6的整数,W的0个或1个亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、-C(O)-、-NR wx-、或-O-替代;其中yn选自0到12的整数,yp为0或1;其中zn选自0到10的整数,Z的0个或1个亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、或-C(O)-替代;-Cyr-选自以下组:6到10元亚芳基、和3到10元饱和的或部分不饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被1到3个取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR r、-SR r、-N(R ra)(R rb)、-C(O)R r、-CO 2R r、-C(O)C(O)R r、-C(O)CH 2C(O)R r、-S(O)R r、-S(O) 2R r、-C(O)N(R ra)(R rb)、-SO 2N(R ra)(R rb)、-OC(O)R r、-N(R)SO 2R r、或被R r任选取代的C 1- 6脂肪族基团;其中每个R r,R ra,R rb各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;所述-L b-表示由2到7个氨基酸构成的肽残基,所述-L b-的肽残基为由选自以下组中的氨基酸形成的肽残基:苯丙氨酸、甘氨酸、丙氨酸、缬氨酸、瓜氨酸、赖氨酸、丝氨酸、谷氨酸、和天冬氨酸;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、和C 1-6脂肪族基团。
- 根据权利要求3-8中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述-L a-为其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn为1、2、3或6,W的1个亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、或-C(O)-替代;其中yn为0、4或8,yp为0或1;其中zn为1、2或3,Z的1个亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、或-C(O)-替代;-Cyr-为3到10元饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被1到3个取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、卤素、-OR r或被R r任选取代的C 1-6脂肪族基团;其中每个R r各自独立地为氢、卤素或C 1-6脂肪族基团;所述-L b-表示由2到4个氨基酸构成的肽残基,所述-L b-的肽残基为由选自以下组中的氨基酸形成的肽残基:苯丙氨酸、甘氨酸、丙氨酸、缬氨酸、瓜氨酸和赖氨酸;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、卤素、-OH和C 1-6脂肪族基团。
- 根据权利要求3-9中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述-L a-为其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn为1、2、3或6,W的1个亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、或-C(O)-替代;其中yn为0、4或8,yp为0或1;其中zn为1、2或3,Z的1个亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、或-C(O)-替代;-Cyr-为3到10元饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被1到3个取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、卤素、-OR r或被R r任选取代的C 1-6脂肪族基团;其中每个R r各自独立地为氢、卤素或C 1-6脂肪族基团;所述-L b-选自以下组:所述-L c-为其中R L1、R L2各自独立地选自以下组:氢、卤素、-OH和C 1-6脂肪族基团。
- 根据权利要求3-10中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述-L a-为其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn为1、2、3或6,W的1个亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、或-C(O)-替代;其中yn为0、4或8,yp为0或1;其中zn为1、2或3,Z的1个亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、或-C(O)-替代;-Cyr-为3到10元饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被1到3个取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、卤素、-OR r或被R r任选取代的C 1-6脂肪族基团;其中每个R r各自独立地为氢、卤素或C 1-6脂肪族基团;所述-L b-为所述-L c-为其中R L1、R L2各自独立地选自以下组:氢、卤素、-OH和C 1-6脂肪族基团。
- 一种通式(II-F x)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中:所述L x为L ax-L b-L c-;所述L ax-选自以下组:其中R hal为碘或溴;其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn选自至少为0的整数,W的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR wx-、-O-、-S-、-SO-、-SO 2-、-P(R wx)-、-P(=O)(R wx)-、-N(R wx)SO 2-、-SO 2N(R wx)-、-C(=S)-、-C(=NR wx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中yn选自至少为0的整数,yp为0或1;其中zn选自至少为0的整数,Z的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR zx-、-O-、-S-、-SO-、-SO 2-、-P(R zx)-、-P(=O)(R zx)-、-N(R zx)SO 2-、-SO 2N(R zx)-、-C(=S)-、-C(=NR zx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;-Cyr-选自以下组:6到10元亚芳基、5到8元亚杂芳基、3到10元亚杂环基、和3到10元饱和的或部分不饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被至少1个的取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR r、-SR r、-N(R ra)(R rb)、-C(O)R r、-CO 2R r、-C(O)C(O)R r、-C(O)CH 2C(O)R r、-S(O)R r、-S(O) 2R r、-C(O)N(R ra)(R rb)、-SO 2N(R ra)(R rb)、-OC(O)R r、-N(R)SO 2R r、或被R r任选取代的C 1- 6脂肪族基团;其中每个R r,R ra,R rb各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;所述-L b-表示由2到7个氨基酸构成的肽残基;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、和C 1-6脂肪族基团;其中X 1为饱和的C,所述X 1被R n取代;环A选自以下组:3到10元饱和的或部分不饱和的杂环基,和3到10元饱和的或部分不饱和的碳环基,其中所述环A被0个或至少1个取代基R 1a取代;当环A为3到10元饱和的或部分不饱和的碳环基时,所述环A被p个L 2取代,所述L 2不为R n;或者,当环A为3到10元饱和的或部分不饱和的杂环基时,所述环A被p个L 2取代;L 2为-R 2-L 3-,所述R 2用于直接或间接连接配体;L 3为-(C(R 3a)(R 3b)) m-,其中当L 3包含亚甲基单元时,所述L 3的0个或至少1个亚甲基单元各自独立地被-N(R 4)C(O)-、-C(O)N(R 4)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 4-、-O-、-S-、-SO-、-SO 2-、-P(R 4)-、-P(=O)(R 4)-、-N(R 4)SO 2-、-SO 2N(R 4)-、-C(=S)-、-C(=NR 4)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;R 2选自以下组:-O-,-(R 2a)N-,-S-,和-P(=O)(R 2a)-;L 1为-(C(R 5a)(R 5b)) n-,其中当L 1包含亚甲基单元时,所述L 1的0个或至少1个亚甲基单元各自独立地被-N(R 6)C(O)-、-C(O)N(R 6)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 6-、-O-、-S-、-SO-、-SO 2-、-P(R 6)-、-P(=O)(R 6)-、-N(R 6)SO 2-、-SO 2N(R 6)-、-C(=S)-、-C(=NR 6)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中每个R 1a,R 2a,R 3a,R 3b,R 4,R 5a,R 5b,R 6,R n各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、 -S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m,n各自独立地选自至少为0的整数,p为至少为1的整数。
- 根据权利要求1-18中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A选自以下组:3到10元饱和的杂环基、和3到10元饱和的碳环基。
- 根据权利要求1-19中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A为3到10元饱和的碳环基。
- 根据权利要求1-20中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A为3到6元饱和的碳环基。
- 根据权利要求1-21中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A为4元饱和的碳环基。
- 根据权利要求1-21中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A为6元饱和的碳环基。
- 根据权利要求1-19中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A为3到10元饱和的杂环基。
- 根据权利要求1-19和24中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A为3到6元饱和的杂环基。
- 根据权利要求1-19和24-25中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A为3元饱和的杂环基。
- 根据权利要求1-19和24-26中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A包含1个杂原子。
- 根据权利要求1-19和24-27中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A包含1个 氮原子。
- 根据权利要求1-19和24-25中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A为5元饱和的杂环基。
- 根据权利要求1-19和24-25中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A为6元饱和的杂环基。
- 根据权利要求1-19、24-25和29-30中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A包含1个杂原子。
- 根据权利要求1-19、24-25和29-31中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中环A包含1个氮原子。
- 根据权利要求1-32中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述环A被0个取代基R 1a取代。
- 根据权利要求1-34中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述环A被至少1个L 2取代。
- 根据权利要求1-35中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述环A被1个L 2取代。
- 根据权利要求1-36中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中m为0、1或2。
- 根据权利要求1-37中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中m为0,L 3为共价键。
- 根据权利要求1-37中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中m为1,L 3为-C(R 5a)(R 5b)-。
- 根据权利要求1-37和39中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中L 3的0个亚甲基单元被-N(R 4)C(O)-、-C(O)N(R 4)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 4-、-O-、-S-、-SO-、-SO 2-、-P(R 4)-、-P(=O)(R 4)-、-N(R 4)SO 2-、-SO 2N(R 4)-、-C(=S)-、-C(=NR 4)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代。
- 根据权利要求1-37中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中m为2,L 3为-(C(R 3a)(R 3b)) 2-。
- 根据权利要求1-37和41中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中L 3的0个亚甲基单元被-N(R 4)C(O)-、-C(O)N(R 4)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 4-、-O-、-S-、-SO-、-SO 2-、-P(R 4)-、-P(=O)(R 4)-、-N(R 4)SO 2-、-SO 2N(R 4)-、-C(=S)-、-C(=NR 4)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代。
- 根据权利要求1-42中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中n为0或1。
- 根据权利要求1-43中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中n为0,L 1为共价键。
- 根据权利要求1-43中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中n为1,L 1为-C(R 5a)(R 5b)-。
- 根据权利要求1-43和45中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中L 1的1个亚甲基单元被-N(R 6)C(O)-、-C(O)N(R 6)-、-C(O)-、-OC(O)-、-C(O)O-、-NR 6-、-O-、-S-、-SO-、-SO 2-、-P(R 6)-、-P(=O)(R 6)-、-N(R 6)SO 2-、-SO 2N(R 6)-、-C(=S)-、-C(=NR 6)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代。
- 根据权利要求1-43和45-46中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中L 1的1个亚甲基单元被-C(O)-替代。
- 根据权利要求1-47中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 2选自以下组:-O-,-(R 2a)N-,和-S-。
- 根据权利要求1-48中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 2为-O-。
- 根据权利要求1-47中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 2为-(R 2a)N-。
- 根据权利要求1-47和50中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 2a为氢。
- 根据权利要求1-47和50-51中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 2为-HN-。
- 根据权利要求1-52中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 1a为氢。
- 根据权利要求1-53中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 3a,R 3b各自独立地为氢。
- 根据权利要求1-54中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 4为氢。
- 根据权利要求1-55中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对 映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 5a,R 5b各自独立地为氢。
- 根据权利要求1-56中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R 6为氢。
- 根据权利要求1-57中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述R,R a,R b各自独立地为氢。
- 一种化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述化合物包含式(III-A)所示的结构:其中R 1选自以下组:-O-,-(R 2)N-,-P(=O)(R 2)-,和-S-;X为-L 1-CH 2-C(O)-;L 1为-(C(R 3a)(R 3b)) m-,其中L 1的0个或至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代;其中每个R 2,R 3a,R 3b,R 4b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、-S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m选自至少为0的整数,n选自至少为1的整数;当R 1为-O-或-HN-时,L 1的至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代,或者每一个R 3a,R 3b不同时为氢。
- 一种通式(III-E)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中:其中R 1选自以下组:-O-,-(R 2)N-,-P(=O)(R 2)-,和-S-;X为-L 1-CH 2-C(O)-;L 1为-(C(R 3a)(R 3b)) m-,其中L 1的0个或至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代;其中每个R 2,R 3a,R 3b,R 4b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、-S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m选自至少为0的整数,n选自至少为1的整数;当R 1为-O-或-HN-时,L 1的至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代,或者每一个R 3a,R 3b不同时为氢。
- 一种化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其包含式(III-C)所示的结构:所述L为-L a-L b-L c-;所述-L a-选自以下组:其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp,Z为-(C(R za)(R zb)) zn,;其中wn选自至少为0的整数,W的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR wx-、-O-、-S-、-SO-、-SO 2-、-P(R wx)-、-P(=O)(R wx)-、-N(R wx)SO 2-、-SO 2N(R wx)-、-C(=S)-、-C(=NR wx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中yn选自至少为0的整数,yp为0或1;其中zn选自至少为0的整数,Z的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR zx-、-O-、-S-、-SO-、-SO 2-、-P(R zx)-、-P(=O)(R zx)-、-N(R zx)SO 2-、-SO 2N(R zx)-、-C(=S)-、-C(=NR zx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;-Cyr-选自以下组:6到10元亚芳基、5到8元亚杂芳基、3到10元亚杂环基、和3到10元饱和的或部分不饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被至少1个的取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR r、-SR r、-N(R ra)(R rb)、-C(O)R r、-CO 2R r、-C(O)C(O)R r、-C(O)CH 2C(O)R r、-S(O)R r、-S(O) 2R r、-C(O)N(R ra)(R rb)、-SO 2N(R ra)(R rb)、-OC(O)R r、-N(R)SO 2R r、或被R r任选取代的C 1- 6脂肪族基团;其中每个R r,R ra,R rb各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;所述-L b-表示由2到7个氨基酸构成的肽残基;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、和C 1-6脂肪族基团;其中R 1选自以下组:-O-,-(R 2)N-,-P(=O)(R 2)-,和-S-;X为-L 1-CH 2-C(O)-;L 1为-(C(R 3a)(R 3b)) m-,其中L 1的0个或至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代;其中每个R 2,R 3a,R 3b,R 4b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、-S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m选自至少为0的整数,n选自至少为1的整数;当R 1为-O-或-HN-时,L 1的至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代,或者每一个R 3a,R 3b不同时为氢。
- 一种化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其包含式(III-D)所示的结构:其中,Ab为配体,平均连接数N a为1到10的整数或小数;所述L为-L a-L b-L c-;所述-L a-选自以下组:其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp,Z为-(C(R za)(R zb)) zn,;其中wn选自至少为0的整数,W的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、- C(O)-、-OC(O)-、-C(O)O-、-NR wx-、-O-、-S-、-SO-、-SO 2-、-P(R wx)-、-P(=O)(R wx)-、-N(R wx)SO 2-、-SO 2N(R wx)-、-C(=S)-、-C(=NR wx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中yn选自至少为0的整数,yp为0或1;其中zn选自至少为0的整数,Z的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR zx-、-O-、-S-、-SO-、-SO 2-、-P(R zx)-、-P(=O)(R zx)-、-N(R zx)SO 2-、-SO 2N(R zx)-、-C(=S)-、-C(=NR zx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;-Cyr-选自以下组:6到10元亚芳基、5到8元亚杂芳基、3到10元亚杂环基、和3到10元饱和的或部分不饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被至少1个的取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR r、-SR r、-N(R ra)(R rb)、-C(O)R r、-CO 2R r、-C(O)C(O)R r、-C(O)CH 2C(O)R r、-S(O)R r、-S(O) 2R r、-C(O)N(R ra)(R rb)、-SO 2N(R ra)(R rb)、-OC(O)R r、-N(R)SO 2R r、或被R r任选取代的C 1- 6脂肪族基团;其中每个R r,R ra,R rb各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;所述-L b-表示由2到7个氨基酸构成的肽残基;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、和C 1-6脂肪族基团;其中R 1选自以下组:-O-,-(R 2)N-,-P(=O)(R 2)-,和-S-;X为-L 1-CH 2-C(O)-;L 1为-(C(R 3a)(R 3b)) m-,其中L 1的0个或至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代;其中每个R 2,R 3a,R 3b,R 4b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、-S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m选自至少为0的整数,n选自至少为1的整数;当R 1为-O-或-HN-时,L 1的至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代,或者每一个R 3a,R 3b不同时为氢。
- 根据权利要求63所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述配体Ab为抗体或其抗原 结合片段。
- 根据权利要求63-64中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述配体Ab选自以下组:嵌合抗体、人源化抗体和全人源抗体。
- 根据权利要求63-65中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中所述配体Ab靶向以下组:HER2、HER3、B7H3、TROP2、Claudin 18.2、CD30、CD33、CD70和EGFR。
- 根据权利要求60-66中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述-L a-选自以下组:其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn选自2到6的整数,W的0个或1个亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、-C(O)-、-NR wx-、或-O-替代;其中yn选自0到12的整数,yp为0或1;其中zn选自0到10的整数,Z的0个或1个亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、或-C(O)-替代;-Cyr-选自以下组:6到10元亚芳基、和3到10元饱和的或部分不饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被1到3个取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR r、-SR r、-N(R ra)(R rb)、-C(O)R r、-CO 2R r、-C(O)C(O)R r、-C(O)CH 2C(O)R r、-S(O)R r、-S(O) 2R r、-C(O)N(R ra)(R rb)、-SO 2N(R ra)(R rb)、-OC(O)R r、-N(R)SO 2R r、或被R r任选取代的C 1- 6脂肪族基团;其中每个R r,R ra,R rb各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;所述-L b-表示由2到7个氨基酸构成的肽残基,所述-L b-的肽残基为由选自以下组中的氨基酸形成的肽残基:苯丙氨酸、甘氨酸、丙氨酸、缬氨酸、瓜氨酸、赖氨酸、丝氨酸、谷氨酸、和天冬氨酸;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、 -OC(O)H、-N(H)SO 2H、和C 1-6脂肪族基团。
- 根据权利要求60-67中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述-L a-为其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn为1、2、3或6,W的1个亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、或-C(O)-替代;其中yn为0、4或8,yp为0或1;其中zn为1、2或3,Z的1个亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、或-C(O)-替代;-Cyr-为3到10元饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被1到3个取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、卤素、-OR r或被R r任选取代的C 1-6脂肪族基团;其中每个R r各自独立地为氢、卤素或C 1-6脂肪族基团;所述-L b-表示由2到4个氨基酸构成的肽残基,所述-L b-的肽残基为由选自以下组中的氨基酸形成的肽残基:苯丙氨酸、甘氨酸、丙氨酸、缬氨酸、瓜氨酸和赖氨酸;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、卤素、-OH和C 1-6脂肪族基团。
- 根据权利要求60-68中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述-L a-为其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn为1、2、3或6,W的1个亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、或-C(O)-替代;其中yn为0、4或8,yp为0或1;其中zn为1、2或3,Z的1个亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、或-C(O)-替代;-Cyr-为3到10元饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被1到3个取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、卤素、-OR r或被R r任选取代的C 1-6脂肪族基团;其中每个R r各自独立地为氢、卤素或C 1-6脂肪族基团;所述-L b-选自以下组:所述-L c-为其中R L1、R L2各自独立地选自以下组:氢、卤素、-OH和C 1-6脂肪族基团。
- 根据权利要求60-69中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,所述-L a-为其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp-,Z为-(C(R za)(R zb)) zn;其中wn为1、2、3或6,W的1个亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、或-C(O)-替代;其中yn为0、4或8,yp为0或1;其中zn为1、2或3,Z的1个亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、或-C(O)-替代;-Cyr-为3到10元饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被1到3个取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、卤素、-OR r或被R r任选取代的C 1-6脂肪族基团;其中每个R r各自独立地为氢、卤素或C 1-6脂肪族基团;所述-L b-为所述-L c-为其中R L1、R L2各自独立地选自以下组:氢、卤素、-OH和C 1-6脂肪族基团。
- 一种通式(III-F)所示的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中:所述L x为L ax-L b-L c-;所述L ax-选自以下组:其中R hal为碘或溴;其中,W为-(C(R wa)(R wb)) wn-,Y为-(OCH 2CH 2) yn-O yp,Z为-(C(R za)(R zb)) zn,;其中wn选自至少为0的整数,W的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R wx)C(O)-、-C(O)N(R wx)-、- C(O)-、-OC(O)-、-C(O)O-、-NR wx-、-O-、-S-、-SO-、-SO 2-、-P(R wx)-、-P(=O)(R wx)-、-N(R wx)SO 2-、-SO 2N(R wx)-、-C(=S)-、-C(=NR wx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;其中yn选自至少为0的整数,yp为0或1;其中zn选自至少为0的整数,Z的0个或至少1个的亚甲基单元各自独立地被-Cyr-、-N(R zx)C(O)-、-C(O)N(R zx)-、-C(O)-、-OC(O)-、-C(O)O-、-NR zx-、-O-、-S-、-SO-、-SO 2-、-P(R zx)-、-P(=O)(R zx)-、-N(R zx)SO 2-、-SO 2N(R zx)-、-C(=S)-、-C(=NR zx)-、-N=N-、-C=N-、-N=C-或-C(=N 2)-替代;-Cyr-选自以下组:6到10元亚芳基、5到8元亚杂芳基、3到10元亚杂环基、和3到10元饱和的或部分不饱和的亚碳环基,其中所述-Cyr-是未取代的或独立地被至少1个的取代基R cx取代;其中每个R wa,R wb,R za,R zb,R wx,R zx,R cx各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR r、-SR r、-N(R ra)(R rb)、-C(O)R r、-CO 2R r、-C(O)C(O)R r、-C(O)CH 2C(O)R r、-S(O)R r、-S(O) 2R r、-C(O)N(R ra)(R rb)、-SO 2N(R ra)(R rb)、-OC(O)R r、-N(R)SO 2R r、或被R r任选取代的C 1- 6脂肪族基团;其中每个R r,R ra,R rb各自独立地为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;所述-L b-表示由2到7个氨基酸构成的肽残基;所述-L c-选自以下组:其中R L1、R L2各自独立地选自以下组:氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、和C 1-6脂肪族基团;其中R 1选自以下组:-O-,-(R 2)N-,-P(=O)(R 2)-,和-S-;X为-L 1-CH 2-C(O)-;L 1为-(C(R 3a)(R 3b)) m-,其中L 1的0个或至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代;其中每个R 2,R 3a,R 3b,R 4b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OR、-SR、-N(R a)(R b)、-C(O)R、-CO 2R、-C(O)C(O)R、-C(O)CH 2C(O)R、-S(O)R、-S(O) 2R、-C(O)N(R a)(R b)、-SO 2N(R a)(R b)、-OC(O)R、-N(R)SO 2R、或被R任选取代的C 1-6脂肪族基团;其中每个R,R a,R b各自独立为氢、氕、氘、氚、卤素、-NO 2、-CN、-OH、-SH、-NH 2、-C(O)H、-CO 2H、-C(O)C(O)H、-C(O)CH 2C(O)H、-S(O)H、-S(O) 2H、-C(O)NH 2、-SO 2NH 2、-OC(O)H、-N(H)SO 2H、或C 1-6脂肪族基团;m选自至少为0的整数,n选自至少为1的整数;当R 1为-O-或-HN-时,L 1的至少1个亚甲基单元各自独立地被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代,或者每一个R 3a,R 3b不同时为氢。
- 根据权利要求60-77中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中X为-L 1-CH 2-C(O)-,L 1为-(C(R 3a)(R 3b)) m-,m不为0,每一个R 3a,R 3b不同时为氢。
- 根据权利要求60-78中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中m为1,L 1为-C(R 3a)(R 3b)-。
- 根据权利要求60-79中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中L 1的0个亚甲基单元被-C(O)-、-C(=S)-、-C(=NR 4b)-或-C(=N 2)-替代。
- 根据权利要求60-80中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 3a为C 1-6脂肪族基团。
- 根据权利要求60-81中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 3b为氢或C 1-6脂肪族基团。
- 根据权利要求60-82中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 3a为C 1-6脂肪族基团,R 3b为氢。
- 根据权利要求60-83中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 3a为甲基,R 3b为氢。
- 根据权利要求60-82中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 3a为C 1-6脂肪族基团,R 3b为C 1-6脂肪族基团。
- 根据权利要求60-82和85中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 3a为甲基,R 3b为C 1-6脂肪族基团。
- 根据权利要求60-82和85-86中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 3a为甲基,R 3b为甲基。
- 根据权利要求60-87中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 1为-O-或-HN-。
- 根据权利要求60-87中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 1为-(R 2)N-或-S-,且R 2不为氢。
- 根据权利要求60-87和89中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 1为-S-。
- 根据权利要求60-87和89中任一项所述的化合物或其互变异构体、内消旋体、外消旋 体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 1为-(R 2)N-。
- 根据权利要求60-87、89和91中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 2为氢。
- 根据权利要求60-87、89和91中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 1为-(R 2)N-,且R 2为C 1-6脂肪族基团。
- 根据权利要求60-87、89、91和93中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 2为甲基。
- 根据权利要求60-94中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R 4b为氢。
- 根据权利要求60-95中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,其中R,R a,R b为氢。
- 制备权利要求1、3-15和19-58中任一项所述的式(II-A)、式(II-C x)、式(II-D x)所示化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合 物形式,或其可药用的盐的方法,其包括将配体Ab与权利要求16-58中任一项所述的式(II-F x)所示的结构接触。
- 制备权利要求60、62-74和78-96中任一项所述的式(III-A)、式(III-C)、式(III-D)所示化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐的方法,其包括将配体Ab与权利要求75-96中任一项所述的式(III-F)所示的结构接触。
- 一种药物组合物,其含有权利要求1-97中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐,和药学上可接受的载体。
- 含有权利要求1-97中任一项所述的化合物或其互变异构体、内消旋体、外消旋体、对映异构体、非对映异构体、或其混合物形式,或其可药用的盐和/或权利要求100所述的药物组合物在制备用于治疗和/或预防肿瘤的药物中的用途。
- 如权利要求102所述的用途,所述肿瘤选自与以下组表达相关的肿瘤:HER2、HER3、B7H3、TROP2、Claudin 18.2、CD30、CD33、CD70和EGFR。
- 如权利要求101-102中任一项所述的用途,所述肿瘤选自以下组:肺癌、肾癌、尿道癌、结肠直肠癌、前列腺癌、多形性成胶质细胞瘤、卵巢癌、胰腺癌、乳腺癌、黑色素瘤、肝癌、膀胱癌、胃癌、和食道癌。
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211403184.7A CN116199739A (zh) | 2020-09-30 | 2021-09-29 | 一种抗肿瘤化合物及其制备方法和应用 |
MX2023003778A MX2023003778A (es) | 2020-09-30 | 2021-09-29 | Compuesto antitumoral, metodo de preparacion y uso del mismo. |
CA3195515A CA3195515A1 (en) | 2020-09-30 | 2021-09-29 | Anti-tumor compound and preparation method and use thereof |
JP2023520181A JP2023551355A (ja) | 2020-09-30 | 2021-09-29 | 抗腫瘍化合物並びにその調製方法及び使用 |
CN202211407530.9A CN115925796A (zh) | 2020-09-30 | 2021-09-29 | 一种抗肿瘤化合物及其制备方法和应用 |
EP21874533.9A EP4223318A1 (en) | 2020-09-30 | 2021-09-29 | Antitumor compound, and preparation method therefor and use thereof |
KR1020237011470A KR20230079085A (ko) | 2020-09-30 | 2021-09-29 | 항종양 화합물 및 그의 제조 방법 및 용도 |
AU2021354823A AU2021354823A1 (en) | 2020-09-30 | 2021-09-29 | Antitumor compound, and preparation method therefor and use thereof |
IL301793A IL301793A (en) | 2020-09-30 | 2021-09-29 | Anticancer compound and method for its preparation and use |
CN202310152789.1A CN116239601B (zh) | 2020-09-30 | 2021-09-29 | 一种抗肿瘤化合物及其制备方法和应用 |
CN202180018263.3A CN115175705A (zh) | 2020-09-30 | 2021-09-29 | 一种抗肿瘤化合物及其制备方法和应用 |
US17/825,090 US11685742B2 (en) | 2020-09-30 | 2022-05-26 | Anti-tumor compound and preparation method and use thereof |
US17/828,433 US11607459B1 (en) | 2020-09-30 | 2022-05-31 | Anti-tumor compound and preparation method and use thereof |
US18/147,070 US11952384B2 (en) | 2020-09-30 | 2022-12-28 | Anti-tumor compound and preparation method and use thereof |
US18/187,935 US20230331738A1 (en) | 2020-09-30 | 2023-03-22 | Anti-tumor compound and preparation method and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011061580.7 | 2020-09-30 | ||
CN202011061580 | 2020-09-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/825,090 Continuation US11685742B2 (en) | 2020-09-30 | 2022-05-26 | Anti-tumor compound and preparation method and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022068878A1 true WO2022068878A1 (zh) | 2022-04-07 |
Family
ID=80951198
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/121721 WO2022068878A1 (zh) | 2020-09-30 | 2021-09-29 | 一种抗肿瘤化合物及其制备方法和应用 |
Country Status (11)
Country | Link |
---|---|
US (4) | US11685742B2 (zh) |
EP (1) | EP4223318A1 (zh) |
JP (1) | JP2023551355A (zh) |
KR (1) | KR20230079085A (zh) |
CN (4) | CN116239601B (zh) |
AU (1) | AU2021354823A1 (zh) |
CA (1) | CA3195515A1 (zh) |
IL (1) | IL301793A (zh) |
MX (1) | MX2023003778A (zh) |
TW (1) | TW202214230A (zh) |
WO (1) | WO2022068878A1 (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023088235A1 (en) * | 2021-11-16 | 2023-05-25 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
WO2023138635A1 (zh) * | 2022-01-18 | 2023-07-27 | 甘李药业股份有限公司 | 一种依喜替康衍生物-抗体偶联物及其医药用途 |
WO2023143365A1 (zh) * | 2022-01-28 | 2023-08-03 | 映恩生物制药(苏州)有限公司 | Her3抗体药物偶联物及其用途 |
WO2023173026A1 (en) * | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2023174401A1 (zh) * | 2022-03-18 | 2023-09-21 | 映恩生物制药(苏州)有限公司 | Gpc3抗体药物偶联物及其用途 |
WO2023216956A1 (zh) * | 2022-05-13 | 2023-11-16 | 四川科伦博泰生物医药股份有限公司 | 喜树碱类化合物及其制备方法和应用 |
WO2023217064A1 (zh) * | 2022-05-09 | 2023-11-16 | 同宜医药(苏州)有限公司 | 一种喜树碱衍生物,基于其的抗体-药物偶联物和药物组合物,及其应用 |
WO2023236949A1 (zh) * | 2022-06-07 | 2023-12-14 | 映恩生物制药(苏州)有限公司 | 抗b7h3抗体-药物偶联物及其用途 |
WO2024026323A1 (en) * | 2022-07-26 | 2024-02-01 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2024022165A1 (zh) * | 2022-07-29 | 2024-02-01 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
WO2024049931A1 (en) | 2022-09-02 | 2024-03-07 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
WO2024067811A1 (en) * | 2022-09-30 | 2024-04-04 | Beigene, Ltd. | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
WO2024078449A1 (en) * | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116239601B (zh) * | 2020-09-30 | 2023-10-13 | 映恩生物制药(苏州)有限公司 | 一种抗肿瘤化合物及其制备方法和应用 |
CN115850291A (zh) * | 2021-09-24 | 2023-03-28 | 石药集团巨石生物制药有限公司 | 喜树碱衍生物及其用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104755494A (zh) | 2012-10-11 | 2015-07-01 | 第一三共株式会社 | 抗体-药物偶联物 |
CN105829346A (zh) * | 2014-01-31 | 2016-08-03 | 第三共株式会社 | 抗her2抗体-药物偶联物 |
US20170035906A1 (en) * | 2014-04-10 | 2017-02-09 | Daiichi Sankyo Company, Limited | (anti-her2 antibody)-drug conjugate |
CN109789211A (zh) * | 2016-10-07 | 2019-05-21 | 第一三共株式会社 | 基于抗her2抗体-药物偶联物施予的耐性癌的治疗 |
WO2020063673A1 (zh) * | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
WO2020063676A1 (zh) * | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
WO2021007435A1 (en) * | 2019-07-10 | 2021-01-14 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
WO2014061277A1 (ja) * | 2012-10-19 | 2014-04-24 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体-薬物コンジュゲート |
CN109106951A (zh) | 2017-08-18 | 2019-01-01 | 四川百利药业有限责任公司 | 一种喜树碱-抗体偶联物 |
CN113260384A (zh) | 2018-11-05 | 2021-08-13 | 西纳福克斯股份有限公司 | 用于靶向表达trop-2的肿瘤的抗体缀合物 |
CN112125915A (zh) | 2019-09-18 | 2020-12-25 | 四川百利药业有限责任公司 | 一种喜树碱衍生物及其偶联物 |
CN116239601B (zh) * | 2020-09-30 | 2023-10-13 | 映恩生物制药(苏州)有限公司 | 一种抗肿瘤化合物及其制备方法和应用 |
EP4227310A1 (en) | 2020-10-12 | 2023-08-16 | Sichuan Baili Pharmaceutical Co. Ltd. | Camptothecin derivative and ligand-drug conjugate thereof |
WO2022078279A1 (zh) | 2020-10-12 | 2022-04-21 | 昆山新蕴达生物科技有限公司 | 抗体-药物偶联物及其应用 |
CN114569739A (zh) | 2020-12-01 | 2022-06-03 | 正大天晴药业集团股份有限公司 | 抗体药物偶联物 |
CN116829561A (zh) | 2021-02-05 | 2023-09-29 | 四川科伦博泰生物医药股份有限公司 | 喜树碱类化合物及其制备方法和应用 |
CN113816969B (zh) | 2021-04-30 | 2024-01-16 | 联宁(苏州)生物制药有限公司 | 依喜替康类化合物、其抗体药物偶联物及其应用 |
CA3219236A1 (en) | 2021-05-07 | 2022-11-10 | ALX Oncology Inc. | Exatecan derivatives and antibody-drug conjugates thereof |
-
2021
- 2021-09-29 CN CN202310152789.1A patent/CN116239601B/zh active Active
- 2021-09-29 WO PCT/CN2021/121721 patent/WO2022068878A1/zh active Application Filing
- 2021-09-29 CN CN202211403184.7A patent/CN116199739A/zh active Pending
- 2021-09-29 CN CN202180018263.3A patent/CN115175705A/zh active Pending
- 2021-09-29 CN CN202211407530.9A patent/CN115925796A/zh active Pending
- 2021-09-29 EP EP21874533.9A patent/EP4223318A1/en active Pending
- 2021-09-29 KR KR1020237011470A patent/KR20230079085A/ko unknown
- 2021-09-29 JP JP2023520181A patent/JP2023551355A/ja active Pending
- 2021-09-29 CA CA3195515A patent/CA3195515A1/en active Pending
- 2021-09-29 IL IL301793A patent/IL301793A/en unknown
- 2021-09-29 TW TW110136259A patent/TW202214230A/zh unknown
- 2021-09-29 AU AU2021354823A patent/AU2021354823A1/en active Pending
- 2021-09-29 MX MX2023003778A patent/MX2023003778A/es unknown
-
2022
- 2022-05-26 US US17/825,090 patent/US11685742B2/en active Active
- 2022-05-31 US US17/828,433 patent/US11607459B1/en active Active
- 2022-12-28 US US18/147,070 patent/US11952384B2/en active Active
-
2023
- 2023-03-22 US US18/187,935 patent/US20230331738A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104755494A (zh) | 2012-10-11 | 2015-07-01 | 第一三共株式会社 | 抗体-药物偶联物 |
CN105829346A (zh) * | 2014-01-31 | 2016-08-03 | 第三共株式会社 | 抗her2抗体-药物偶联物 |
US20170035906A1 (en) * | 2014-04-10 | 2017-02-09 | Daiichi Sankyo Company, Limited | (anti-her2 antibody)-drug conjugate |
CN109789211A (zh) * | 2016-10-07 | 2019-05-21 | 第一三共株式会社 | 基于抗her2抗体-药物偶联物施予的耐性癌的治疗 |
WO2020063676A1 (zh) * | 2018-09-26 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 依喜替康类似物的配体-药物偶联物及其制备方法和应用 |
WO2020063673A1 (zh) * | 2018-09-30 | 2020-04-02 | 江苏恒瑞医药股份有限公司 | 抗b7h3抗体-依喜替康类似物偶联物及其医药用途 |
CN111689980A (zh) * | 2019-05-26 | 2020-09-22 | 四川百利药业有限责任公司 | 一种喜树碱药物及其抗体偶联物 |
WO2021007435A1 (en) * | 2019-07-10 | 2021-01-14 | Cybrexa 2, Inc. | Peptide conjugates of cytotoxins as therapeutics |
Non-Patent Citations (3)
Title |
---|
CHOTHIA ET AL.: "Canonical Structures For the Hypervariable Regions of Immunoglobulins", J. MOL. BIOL., vol. 196, 1987, pages 901, XP024010426, DOI: 10.1016/0022-2836(87)90412-8 |
KABAT E.A. ET AL.: "Sequences of proteins of immunological interest", 1991, NIH |
MACCALLUM ET AL.: "Antibody-Antigen Interactions: Contact Analysis and Binding Site Topography", J. MOL. BIOL., vol. 262, 1996, pages 732, XP002242391, DOI: 10.1006/jmbi.1996.0548 |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023088235A1 (en) * | 2021-11-16 | 2023-05-25 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
AU2022393856A9 (en) * | 2021-11-16 | 2023-08-24 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
US11814394B2 (en) | 2021-11-16 | 2023-11-14 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
AU2022393856B2 (en) * | 2021-11-16 | 2023-11-23 | Genequantum Healthcare (Suzhou) Co., Ltd. | Exatecan derivatives, linker-payloads, and conjugates and thereof |
WO2023138635A1 (zh) * | 2022-01-18 | 2023-07-27 | 甘李药业股份有限公司 | 一种依喜替康衍生物-抗体偶联物及其医药用途 |
WO2023143365A1 (zh) * | 2022-01-28 | 2023-08-03 | 映恩生物制药(苏州)有限公司 | Her3抗体药物偶联物及其用途 |
WO2023173026A1 (en) * | 2022-03-10 | 2023-09-14 | Sorrento Therapeutics, Inc. | Antibody-drug conjugates and uses thereof |
WO2023174401A1 (zh) * | 2022-03-18 | 2023-09-21 | 映恩生物制药(苏州)有限公司 | Gpc3抗体药物偶联物及其用途 |
WO2023217064A1 (zh) * | 2022-05-09 | 2023-11-16 | 同宜医药(苏州)有限公司 | 一种喜树碱衍生物,基于其的抗体-药物偶联物和药物组合物,及其应用 |
WO2023216956A1 (zh) * | 2022-05-13 | 2023-11-16 | 四川科伦博泰生物医药股份有限公司 | 喜树碱类化合物及其制备方法和应用 |
WO2023236949A1 (zh) * | 2022-06-07 | 2023-12-14 | 映恩生物制药(苏州)有限公司 | 抗b7h3抗体-药物偶联物及其用途 |
WO2024026323A1 (en) * | 2022-07-26 | 2024-02-01 | Zeno Management, Inc. | Immunoconjugates and methods |
WO2024022165A1 (zh) * | 2022-07-29 | 2024-02-01 | 杭州爱科瑞思生物医药有限公司 | 依沙替康衍生物及其应用 |
WO2024049931A1 (en) | 2022-09-02 | 2024-03-07 | Merck Sharp & Dohme Llc | Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof |
WO2024067811A1 (en) * | 2022-09-30 | 2024-04-04 | Beigene, Ltd. | Ligand-drug conjugate of exatecan analogue, and medical use thereof |
WO2024078449A1 (en) * | 2022-10-09 | 2024-04-18 | LaNova Medicines Limited | Compounds, compositions and methods |
Also Published As
Publication number | Publication date |
---|---|
CN116239601B (zh) | 2023-10-13 |
US11607459B1 (en) | 2023-03-21 |
MX2023003778A (es) | 2023-04-26 |
CN115175705A (zh) | 2022-10-11 |
JP2023551355A (ja) | 2023-12-08 |
TW202214230A (zh) | 2022-04-16 |
US11685742B2 (en) | 2023-06-27 |
KR20230079085A (ko) | 2023-06-05 |
CN116199739A (zh) | 2023-06-02 |
US11952384B2 (en) | 2024-04-09 |
CA3195515A1 (en) | 2022-04-07 |
EP4223318A1 (en) | 2023-08-09 |
CN115925796A (zh) | 2023-04-07 |
US20230212182A1 (en) | 2023-07-06 |
US20230331738A1 (en) | 2023-10-19 |
US20230086097A1 (en) | 2023-03-23 |
AU2021354823A1 (en) | 2023-03-30 |
IL301793A (en) | 2023-05-01 |
CN116239601A (zh) | 2023-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022068878A1 (zh) | 一种抗肿瘤化合物及其制备方法和应用 | |
TWI826543B (zh) | 依喜替康類似物的配體-藥物偶聯物、其製備方法及其應用 | |
JP2021091692A (ja) | 高い薬剤ロード量を有する抗体−薬剤コンジュゲート | |
CN112125915A (zh) | 一种喜树碱衍生物及其偶联物 | |
CN106573956A (zh) | 澳瑞他汀衍生物及其缀合物 | |
TWI662968B (zh) | 配體-細胞毒性藥物偶聯物、其製備方法及其應用 | |
WO2021190581A1 (zh) | 一种含抗体药物偶联物的药物组合物及其用途 | |
TW201718025A (zh) | 抗體藥物偶聯物的共價鍵連接子及其製備方法與應用 | |
WO2021190602A1 (zh) | 一种抗体药物偶联物的制备方法 | |
CN112839683A (zh) | 含有标记部-抗人抗体Fab片段复合物的药物组合物 | |
CN114306635A (zh) | 包含可裂解接头的化合物及其用途 | |
CN114569739A (zh) | 抗体药物偶联物 | |
WO2023143365A1 (zh) | Her3抗体药物偶联物及其用途 | |
WO2023186015A1 (zh) | B7h4抗体药物偶联物及其用途 | |
WO2023138635A1 (zh) | 一种依喜替康衍生物-抗体偶联物及其医药用途 | |
CN111542324B (zh) | 细胞毒性剂及其偶联物、其制备方法及用途 | |
WO2022262789A1 (zh) | 一种抗肿瘤化合物及其应用 | |
US20240132516A1 (en) | Anti-tumor compound and preparation method and use thereof | |
WO2023174401A1 (zh) | Gpc3抗体药物偶联物及其用途 | |
CN113329769A (zh) | 具有反应性精氨酸的抗体化合物及相关的抗体药物缀合物 | |
WO2023232142A1 (zh) | 一种药物化合物及其用途 | |
WO2022228494A1 (zh) | 抗体偶联药物的制备方法及应用 | |
WO2023207710A1 (zh) | 一类抗体药物偶联物、其药物组合物及应用 | |
CN117430660A (zh) | 奥瑞他汀f类似物及其抗体药物偶联物与应用 | |
WO2024006542A1 (en) | Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21874533 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3195515 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2023520181 Country of ref document: JP Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2021354823 Country of ref document: AU Date of ref document: 20210929 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023005846 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021874533 Country of ref document: EP Effective date: 20230502 |
|
ENP | Entry into the national phase |
Ref document number: 112023005846 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230329 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523440061 Country of ref document: SA |